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Abstract 
 
The identification of aptamers against serum biomarkers of human 
tuberculosis 
DRM, Martin 
MSc. Thesis, Department of Biotechnology, University of the Western Cape 
Tuberculosis (TB) is a global health problem and rated as the second leading 
cause of death after HIV/AIDS. Transmission of TB from one person to the next 
is very rapid in crowded communities. Therefore, it is crucial to identify people 
who are infected as quickly as possible not only to provide treatment but also to 
prevent the spread of the disease. Current TB diagnostic tests such as the culture 
and sputum smear tests are time-consuming, while rapid tests make use of 
antibodies that are costly and have low sensitivity and stability. Great 
improvement has been observed when aptamers are used in place of antibodies in 
rapid diagnostic tests such as lateral flow devices (LFDs). Therefore, the current 
study aims to synthesize and identify aptamers against serum biomarkers for 
development of rapid TB diagnostic tests such as a lateral flow assay. Several TB 
serum biomarkers have been identified and can be used for the diagnosis of TB.  
TB biomarkers expressed in serum samples were identified through in silico 
approach. The biomarkers were expressed in bacterial systems using recombinant 
DNA technology. The recombinant proteins were purified by affinity 
chromatography and further used as targets for the selection of aptamers using 
Systemic Evolution of Ligands by EXponential enrichment (SELEX). Aptamers 
for the selected biomarkers were synthesized based on magnetic-bead based 
SELEX and characterized by electrophoretic mobility shift assay (EMSA), 
Surface Plasmon resonance (SPR) and MicroScale Thermophoresis (MST).  
http://etd.uwc.ac.za/
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Six putative TB serum biomarker proteins were selected from literature, namely, 
Insulin-like Growth Factor Binding Protein 6 (IGFBP6), Interferon-stimulated 
Gene 15 (ISG15), Calcium Binding Protein (S100A9), Retinol Binding Protein 4 
(RBP4), Granzyme A (GrA), and Transgelin-2 (TAGLN2).  
The biomarkers were recombinantly expressed and purified after which they were 
used as targets in SELEX for aptamers synthesis. Aptamers were analysed by in 
silico method and the ones with highly conserved motifs were selected. The 
selected aptamers were synthesized and later characterized. The aptamers that 
show high affinity and specificity for the biomarkers will be used for the 
fabrication of a rapid lateral flow device for TB screening. Such a test would 
allow for a short diagnostic turnaround time, and hence expedite treatment. 
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CHAPTER 1 
LITERATURE REVIEW 
1.1 Introduction 
TB is a worldwide health problem, and the 10
th
 most common cause of death 
globally (WHOa, 2018).  Tuberculosis (TB) is a disease which usually affects the 
lungs and is caused by the bacterium, Mycobacterium tuberculosis. TB can also 
affect other parts of the body, such as the brain, the kidneys, or the spine. TB is 
spread when droplets of nuclei containing M. tuberculosis are expelled into the 
air by infected individuals and inhaled by uninfected individuals (Warner, 2015). 
However, not everyone infected with M. tuberculosis becomes sick. As a result, 
two TB-related conditions exist; latent and active TB infection (Fogel, 2015). 
Individuals with active TB show symptoms such as chest pain, constant coughing 
for 3 weeks or longer, hemoptysis (i.e. coughing up blood), weight loss, loss of 
appetite, night sweats, fever and fatigue. These individuals are also infectious and 
can transfer the disease to other persons. Individuals who are latently infected 
with M. tuberculosis do not have the symptoms of the disease and are also not 
infectious (Fogel, 2015). It is estimated that one third of the world population is 
infected with M. tuberculosis, but only one tenth of these individuals will develop 
active TB in their lifetime (Falzon et al., 2016; WHOa, 2018). 
The diagnosis of active TB can only be confirmed when there is definite evidence 
of M. tuberculosis presence in the patient’s body. However, diagnosing TB 
promptly and accurately remains a significant medical challenge, particularly in 
poor resource settings (Huddart et al., 2016).  
http://etd.uwc.ac.za/
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Commonly used TB diagnostic techniques include the sputum culture test, 
GeneXpert molecular test and the Line Probe Assay. The sputum culture test has 
been in practice for over a century and is still regarded as the mainstay technique 
for the diagnosis of TB (Zhou, 2015). However, this test has a number of 
limitations; it is widely used to detect acid-fast bacilli from the sputum (Davies 
and Pai, 2008), takes about 4 - 8 weeks and cannot be used for TB diagnosis in 
children under the age of 5 years (Boehme and Nabeta, 2010; Lange and Mori, 
2010). Other molecular test TB tests such as the GeneXpert and the Line Probe 
Assay are quite expensive for use in low resource settings; it requires specialized 
equipment and highly trained personnel to perform the tests (Falzon et al., 2016). 
Moreover, the antibodies used in these diagnostic tests for the detection of TB-
specific antigens often have poor sensitivity and specificity (Steingart et al., 
2009). This poor sensitivity often stems from the low stability of antibodies in 
harsh environmental conditions. Thus, to overcome these challenges, effective 
diagnostic strategies that will be rapid, sensitive and cost-effective are urgently 
required. DNA aptamers are short oligonucleotides that can replace antibodies in 
diagnostic tests.  These molecules can fold into specific 3D conformations, which 
is dependent on their nucleotide sequence. These 3D conformations can provide 
these molecules the structural specificity that is required for binding to biomarker 
proteins. DNA aptamers can be produced synthetically, which means their 
production costs are lower than that of antibodies (Shigdar et al., 2013). They are 
also more stable than antibodies, which mean that they can be used to produce 
diagnostic tests that are more specific and more cost effective. 
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1.2 Tuberculosis 
It is hyphothesized that the genus Mycobacterium originated more than 150 
million years ago. Egyptian mummies, dating back to 2400 BC, showed skeletal 
deformities that are typical of tuberculosis. The French physician Theophile 
Laennac, was the first to identify signs of pulmonary and extrapulmonary TB in 
the 18
th
 century. The organism causing TB was identified by Robert Koch in 
1882 using the methylene blue staining developed by Paul Ehrlich. The term 
"tuberculosis" was first used by Johann Lukas Schönlein in the mid 19
th
 century 
(Barberis, et al., 2017).  
While M. tuberculosis causes TB in humans, other Mycobacterium species such 
as the M. africanum, M. caprae, M. bovis, M. microti, M. mungi, M. pinnipedi 
and M. canetti are known to cause TB in animals. There are over 190 species in 
the Mycobacterium genus. They share several common features; they are non-
motile, aerobic, acid-fast bacteria, their cell wall is rich in mycolic acids, and as a 
result their cell wall is thicker than most bacteria (Blouin, 2015).  
Despite their several similarities, specific markers can be used to distinguish 
species in the Mycobacterium genus as shown in Table 1.1. Table 1.1 highlights 
some of the molecular markers used to differentiate the Mycobacterium strains, 
through single point mutations or combinations of polymorphisms found in 
Mycobacterium genes. For example, mutations in gene OxyR have been used to 
distinguish M. caprae and M. bovis from the other members of the 
Mycobacterium genus.  
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Interestingly, M. caprae and M. bovis look similar but differ when a single 
nucleotide polymorphism (SNP) occurs in gene gyrB as shown in the Table 1.1.  
Table 1. 1: An overview of the selected nucleotide markers present in the Mycobacterium 
strains (Rodriguez-Campos et al., 2014) 
Mycobacterium strains M. 
tubercul
osis  
M. 
afrianum 
M. 
mungi 
M. pinnipedii M. 
microti 
M. caprae M. bovis 
M. bovis BCG 
OxyRN285 mutation (G to A)a G G ND G G A A 
pncAC57 mutation (CAC to GAC) CAC CAC ND CAC CAC GAC GAC 
katGC203 (ACC to ACT) and C463 
(CTG to CGG) 
ACC; V ND; CTG ND; ND ACT; CTG ACT; 
CTG 
ACT; 
CTG 
ACT; CTG 
        
mmpL6n551 mutation (C to G) C C ND G G G G 
gyrAc95 mutation (AGC to ACC) V ACC ND ACC ACC ACC ACC 
gyrB mutation at n675 (C to T), 
756 (G to A), 1311 (T to G), 1410 
(C to T) and 1450 (G to T)   
C,G,T,C,
G 
C,G,T,C,T C,G,T,C,
T 
C,G,T,C,T T,G,T,
C,T 
C,A,G,C,
T 
C,A,T,T,T 
Rv2042cc38 T T T T T T T 
Note: The superscript denotes the mutation position at either the codon (c) or the nucleotide (n) 
of the gene while the V and ND represent variable and no data values respectively. OxyR, pncA, 
katG, mmpL, gyr and Rv2042 are the genes used in classical tests to determine the MTBC lineage 
and species based on SNPs. 
 
1.3 Epidemiology of TB 
Nearly 10 million TB infections were reported worldwide in 2017, and about 1.6 
million people died due to this disease. About 95 % of these deaths occurred in 
low and middle-income countries (WHOa, 2018). While more men significantly 
contract and die from TB than women. However, women are severely affected 
during their productive years and during pregnancy. In 2017, an estimated 3.2 
million women fell ill with TB where close to half a million of them died from it 
(WHOb, 2018). TB and HIV-AIDS are comorbidities.  
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Patients with TB infection are often also infected with HIV, because HIV positive 
individuals have a compromised immune system that allows latent TB infection 
to become active (Bell and Noursadeghi, 2017). 
South Africa is one of 6 countries accounting for 60% of the global TB burden 
(WHOa, 2018). Due to its rapid and ease of transmission, TB presents a threat to 
human health. Despite efforts to eradicate this disease, TB remains a threat. 
Socio-economic factors, inadequate therapeutics and failure to diagnose the 
disease at an early stage are among the reasons why this disease remains so 
prominent. The development of Multi-Drug Resistant TB (MDR-TB) is another 
major concern. Poor patient compliance with anti-TB treatment among TB 
patients and sporadic drug shortages are major contributing factors in the 
development of MDR-TB. An estimated of 480 000 global cases of MDR-TB 
have been reported in 2014 (Falzon et al., 2016).  Nearly 26 000 of these cases 
were South African patients. Approximately 6.7 % of these cases were patients 
who were previously on medication, while approximately 1.8 % were new MDR-
TB cases (Budgell et al., 2016). Left untreated, patients with MDR-TB can 
develop Extensively Drug Resistant TB (XDR-TB). An estimated 10 % of MDR-
TB patients develop XDR-TB within the same year of diagnosis (Falzon et al., 
2016). XDR-TB is considered untreatable and responds weakly to available TB 
medication, including the most effective second-line anti-TB drugs such as 
rifampicin, ethambutol, isoniazid and pyrazinamide.  
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1.4 Pathogenesis and the control of TB  
It is quite challenging to fully understand the pathogenesis of TB and the 
protective role the immune system plays during TB infection because the bacteria 
interact with the host immunity in a sophisticated manner (Walzl et al., 2011). In 
patients with active TB, M. tuberculosis triggers inflammation and induce an 
attack on the immune cells which is comparable to oxidative stress (Pieters, 
2008). Upon TB infection, the M. tuberculosis induces the expression of 
superoxide dismutase (SOD) to prevent oxidative stress. This was confirmed in a 
study that observed high levels of expression of SOD in TB patients compared to 
the lung cancer patients (Wang et al., 2013). SOD is a radical scavenging enzyme 
which inhibits inflammation in the extracellular spaces within the lungs (Nozik-
Grayck et al., 2005; Gao et al., 2008). In the presence of SOD, lesions form 
within the affected regions, suggesting an active role for oxidative stress in the 
pathogenesis of the TB. The development of the lesions are caused by the 
difference in the homeostatic states between the enzyme and the reactive oxygen 
species (ROS) (Wang et al., 2013). Nevertheless, in an uncompromised immune 
system, the M. tuberculosis infection can still be contained by the immune cells 
(Behar et al., 2010) as will be discussed in the mechanism of latent TB (Section 
1.6).  
It is speculated that some individuals may combat M. tuberculosis by employing 
the effector mechanisms of neutrophils within the innate immune system (Warren 
et al., 2017). Others clear the bacteria by adaptive immunity through the T cells 
(Jasenosky et al., 2015). The T cells are of two types, the short-time memory T 
cells and the central memory T cells.  
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The short-time memory T cells remain for a short time when the bacteria are 
destroyed, while the central memory T cells are kept for life (Walzl et al., 2011).  
When the host immunity fails to eradicate the M. tuberculosis during the latent 
state, the bacteria remains viable for an extended period, and only becomes active 
when the host defence weakens. This mechanism is, however, not fully 
understood (Walzl et al., 2011).  
The host T cell-mediated immunity is crucial for the regulation of M. tuberculosis 
growth. The presence of the bacteria activates immune cells that express CD4 and 
interleukin (IL) 12 (e.g. macrophages, neutrophils and human B-lymphoblastoid). 
The CD4+ cells mature and promotes the activation of the interferon (IFN) –γ, 
while IL-12 cells activate T helper (TH1) cells to contain the bacteria (Lawn and 
Churchyard, 2009). However, when the immune system is weak, the risk of M. 
tuberculosis infection is elevated as evidenced in HIV
+
 individuals.  In fact, 
immune-compromised individuals are more susceptible to M. tuberculosis co-
infection (Lawn and Churchyard, 2009).  
1.5 Animal-Borne TB transmission 
As mentioned earlier, M. tuberculosis is also present in domestic animals such as 
the pets and the cattle (Angkawanish et al., 2010; Parsons et al., 2008). M. 
tuberculosis infection in animals can also spread to humans especially when food 
products (e.g. raw cheese and unpasteurized milk) produced from M. bovis 
infected animals are consumed. Domestic cattle are more susceptible to bovine 
TB than other animals (Senthilingam, 2015).  
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In fact, up to 2000 cases where TB was transferred from animals to humans was 
reported in the U.S./Mexico border, between 2006 and 2013.  
1.6 Stages of TB infection 
M. tuberculosis grows most successfully in tissues with high oxygen content, 
such as the lungs. There are two stages of TB infection, the latent and the active 
or virulent stages (Jeong et al., 2015). M. tuberculosis mostly enters the body 
through the inhalation of infected aerosols. The bacteria are then detected and 
engulfed by the macrophages. At this stage, the bacterial replication is stopped 
and if the infected person’s immune systems functions optimally, they are 
eventually destroyed. If the bacteria are not destroyed, they remain functionless 
and are contained in the immune cells for some period and the infected individual 
is therefore latently infected. When the immune system weakens or the 
macrophages harbouring the bacterium die, they replicate abundantly spreading 
to the other parts of the body (Peruń et al., 2017). The infection spread through 
either lymphatic channels or the bloodstream to the distant tissues and organs 
such as regional lymph nodes, the apex of the lungs, kidneys, brain and the bones. 
At this stage, the latent bacteria become active and the person develops active or 
virulent TB as summarized in Figure 1.1 (Behar et al., 2010). Individuals with 
HIV co-infection have been reported to have an increased risk of latent TB 
reactivation (Montales et al., 2015).  
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Figure 1.1: The two stages of TB. In latent TB, the bacteria is contained by the immune cells 
while in active TB, the immune system is weakened and cannot offer protection against the 
invading bacteria (Behar et al., 2010). 
 
Infection with M. tuberculosis either causes Pulmonary TB (PTB), Extra 
Pulmonary TB (EPTB) or lymph node infection. In PTB, the infection is initially 
localised at the upper area of the pulmonary lobe from where it spreads to other 
parts of the body if it escapes the immune defence system (Hunter, 2016). The 
infection might spread to the central nervous system, resulting in tubercular 
meningitis, which could be fatal if not treated (Michos et al., 2006). The infection 
might also spread to the extra-pulmonary sites resulting in the formation of EPTB 
diseases such as the cervical adenopathy and lymphatic TB (Lee, 2015). Lymph 
node infection begins from the neck region where the bacteria are mostly 
localised.  
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This causes lymphadenitis or lymph node infection and is usually diagnosed in 
children below the age of 5 years. However, in countries that experience hot 
weather conditions, bacteria other than M. tuberculosis can also cause the 
symptoms. In adults, TB is manifested more in the lungs than in the lymph nodes. 
In fact, PTB occurs in 80 % of TB patients while the lymph node infection arises 
in only ±20 % of active TB patients, with the risk increasing in immune-
compromised individuals such as those co-infected with HIV (Bell and 
Noursadeghi, 2017).  
1.7 Current TB diagnostic techniques and their limitations 
A number of clinical laboratory TB diagnostic tests are available. These tests are 
discussed below.  
1.7.1 Chest X-ray and Lung Ultra-sound 
M. tuberculosis infects primarily the lungs after which it then spreads to other 
parts of the body. When the lungs are infected, the immune cells trigger an 
inflammatory response that can damage the lungs and other organs. The lungs 
then gradually develop scar tissue which can be visualised by a chest X-ray or a 
lung Ultra-sound (Sperandeo et al., 2017; Ball et al., 2017). The chest X-ray 
Portable X-ray units capable of performing chest X-ray can approximately cost 
$600 to $800. If uninsured, patient cost of a chest X-ray in the US is $200 to 
$400 or, if insured, a co-payment of $10 to $50 is required (Wang et al., 2018). 
On the other hand, the chest ultrasound is regarded cheaper than chest X-ray, 
costing on average one third to half as much as chest X-ray (Amatya, et al., 
2018).   
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Despite extensive technological advancement, these techniques however cannot 
discriminate lesions caused by lung cancer from the ones arising from M. 
tuberculosis infection (Del Ciello et al., 2017). However, the presence of other 
lung diseases such as lung cancer and pneumonia can result in false positive TB 
result. Additionally, a negative diagnosis by chest X-ray does not mean the 
patient does not have EPTB.  
Consequently, chest X-ray results should always be confirmed with other TB 
diagnostics tests. Although the turn-around time for the results of chest X-ray test 
is relatively quick when compared to some other TB tests, this test requires 
specialised equipment and trained personnel. In low resource settings such as 
South Africa this can be a major challenge.  
1.7.2 Tuberculin skin test (TST) 
The TST is used to test if a person has been exposed to M. tuberculosis, either 
from a previous tuberculosis vaccination, or from environmental exposure to the 
bacterium. TST involves the injection of a small amount of tuberculin fluid or TB 
protein (antigens) into the skin of the patient’s forearm. The fluid contains 
Purified Protein Derivative (PPD), which is a protein extract of M. tuberculosis. 
When the body is exposed to M. tuberculosis, an active immunity develops and 
antibodies are produced that will remain in the body to provide protection against 
the organism in the future. When PPD is injected, it reacts with the antibodies and 
the inflammation causes swelling of the tissue at the site of injection within 48 – 
72 hrs (Yang et al., 2012). 
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The larger the size of the swelling in the injected area, the higher the likelihood 
that the person is infected with M. tuberculosis. This test cannot discriminate 
between the latent and active TB (Yang et al., 2012). Individuals who have been 
vaccinated with the Bacillus Calmette–Guérin (BCG) vaccine against TB, will 
therefore also test positive for TB with the TST. 
The TST is used in many developed and developing countries to diagnose TB. In 
countries with low rates of TB infection, it is regularly used to diagnose latent TB 
infection. However, this test is not very useful in countries with high rates of TB 
infection since the majority of people in these countries may have latent TB. 
Also, this test is still not affordable to developing countries. The annual cost of 
implementing and maintaining a TST program ranged from $66,564 to $332,728 
for hospitals and $92,886 to $291,248 for health departments in the United States 
(Lambert, et al., 2015). In addition, the cost per PPD Skin Test (including return 
visit for reading) was $49, and the 2-step PPD Skin Test for TB (including return 
visits for readings) was $98 (AITC, 2019).   
1.7.3 Interferon gamma release assays (IGRAs) 
IGRAs measure a patient’s immune response to the presence of TB-causing 
bacteria and are deemed to be more accurate than the TST (Caliskan et al., 2014). 
The procedure involves drawing blood from a person suspected of having TB 
infection and exposing them to TB antigens (Lewinsohn et al., 2017). If the 
person is infected with M. tuberculosis, their peripheral blood lymphocytes will 
respond by producing IFN-ƴ. These assays are considered to be more sensitive 
and only require a single TB test.  
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Recently, the U.S. Food and Drug Administration (FDA) approved two more 
IGRAs, the T-SPOT® TB test (T-SPOT) and the QuantiFERON® TB Gold In-
Tube test (QFT-GIT) (Lewinsohn et al., 2017). The QFT-GIT assay measures the 
IFN-ƴ concentration, while T-SPOT determine the number of cells producing 
IFN-ƴ. The two assays are further compared in Table 1.2.  
Table 1. 2: Comparison between the approved IGRAs (Lewinsohn et al., 2017). 
Feature QFT-GIT T-SPOT 
Test sample  Whole blood analysis  Process peripheral blood 
mononuclear cells (PBMCs) within 
8 hours or if T-Cell Xtend® is used, 
within 30 hours. 
M.tuberculosis 
antigens (for positive 
test results) 
Can detect the peptides singly 
such as the early secretory 
antigenic target 6 (ESAT-6) and 
the culture filtrate protein 10 
(CFP-10). 
Can detect both or separate a 
mixture of the peptides (ESAT-6 
and CFP-10). 
Measurement IFN-ƴ concentration. Number of IFN- ƴ producing cells 
(spots). 
Possible Results Positive, negative, indeterminate. Positive, negative indeterminate, 
borderline. 
 
Despite the advantages highlighted above, these assays are also susceptible to 
errors introduced during sample collection, transportation, processing and 
interpretation of the assay. The tests must be processed within 8 - 30 hours of 
collection while the white blood cells are still viable. These tests are also costly 
which is again a challenge in low resource countries.  T-SPOT is one of the 
options for screening for LTBI partly owing to the viewpoint of cost-
effectiveness.   
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The cost of one test was reported to be $46.61 for T-SPOT and $55.08 for QFT-
GIT, while the total costs (including those incurred for retesting), were $6,525.42 
and $7,711.86 for the T-SPOT and QFT-GIT tests, respectively (Mukai, et al., 
2017). Similarly, although the cost of diagnosis with IGRA and GeneXpert 
MTB/RIF was reported similar in a different study, however, the total healthcare 
cost of IGRA was nearly $15 million more than for the GeneXpert test. This was 
due to the large numbers of false-positive diagnoses triggering inappropriate 
treatment (Little, et al., 2015). These assays may also have lower accuracy in 
HIV infected individuals, children younger than the age of 5, and in people who 
only recently got infected with M. tuberculosis (Falzon et al., 2016). 
Furthermore, these tests cannot differentiate latent and active TB infection 
(Falzon et al., 2016). 
1.7.4 Microscopy tests 
This test involves the preparation of smear of the sputum sample of a patient, 
which is then viewed either using a light microscope or fluorescence microscope 
to detect the presence of M. tuberculosis.  
This test is often used in countries with a high rate of TB infection and involves 
the examination of the sputum to detect a significant number of acid-fast bacteria 
by employing Ziehl-Neelsen (for light microscopy) or acridine-orange stain (for 
fluorescence microscopy) (Caulfield and Wengenack, 2016). A smear of sputum 
(a thin layer of the sample) is placed on a microscope slide, the morphology and 
the presence of the bacteria confirm TB infection (Caulfield and Wengenack, 
2016). This test provides results within hours and is easy to perform.  
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However, the sensitivity of the test is only about 50 – 60 % (Singhal and 
Myneedu, 2015; Caulfield and Wengenack, 2016), especially in countries with a 
high prevalence of HIV co-infection.  The tests also have minimal detection rates 
due to the immuno-compromised nature of the sample, which can suppress the 
number of the viable M. tuberculosis (Siddiqi et al., 2003). Also, delays in 
sample collection and processing might render the test insensitive (Davis et al., 
2013; Kirwan et al., 2016). While light microscopes are commonly available in 
diagnostic laboratories and relatively inexpensive, fluorescence microscopes are 
more expensive and requires specialized training. The costs of diagnosing 
tuberculosis using sputum smear microscopy were estimated to be lower than 
using rapid sputum-based test. The former ranged between $73 to $119 million 
per year, while the latter was $93 to $187 million per year (Pantoja, et al., 2015).  
1.7.5 Sputum culture test  
This test involves the sub-culture of bacteria that are present in the sputum of a 
patient on a suitable nutrient enriched medium. M. tuberculosis can be cultured in 
either the solid or the liquid media. The solid medium can be either egg or agar-
based. The egg-based medium such as the Löwenstein–Jensen (LJ) is the most 
commonly used medium since it has a long shelf life and supports the growth of 
sevaral Mycobacterium species. However, it can be difficult to detect the 
presence of the M. tuberculosis in the early stages of infection (Boum et al., 
2013; Palange et al., 2016). Liquid media such as the Middlebrooks 7H9 and 
Dubos Tween albumin broths, or commercially available culture systems such as 
the Bactec 460TB system, the Bactec Mycobacterial Growth Indicator Tube 
(MGIT) 960 system, VersaTREK (ESP II) culture system and MB/BacT system 
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can also be used to detect M. tuberculosis (Whitelaw and Sturm, 2009). 
Antimicrobial agents (such as penicillin, nalidixic acid, leucomycin and 
cycloheximide) can be added to both solid and the liquid media to prevent 
contamination with other micro-organisms (Whitelaw and Sturm, 2009). 
Upon culturing the M. tuberculosis, a single bacterial colony is isolated from a 
culture with a mixture of different bacteria. An antibiotic resistant colony, which 
is usually composed of tens of millions cells derived from a single cell, is isolated 
after many sub-cultures (Pingle et al., 2014). However, the sputum culture test 
has some drawbacks. In a clinical setting, sub-culturing of the micro-organism is 
more complex, time consuming and expensive than microscopy. Also, with the 
novel diagnostic strategies, each patient requires only one test. In cases of human 
immunodeficiency virus (HIV)-positive people who are presumed to have 
tuberculosis but have a negative detection test result with any of the tests (such as 
rapid sputum or non-sputum biomarker-based test), the liquid culture is used as a 
confirmatory test despite the expenses involved (Pantoja, et al., 2015). The 
estimated unit cost for culture test ranged from $1.63 to $62.01 (Lu, et al., 
2013).  Unit costs for all the tests include only reagents, chemicals, and 
consumables but exclude costs for labor, overhead, space used, and transport. 
This figure amounted to $162 million in an estimated 1.5 million tuberculosis 
cases (Pantoja, et al., 2015).  Furthermore, the turn-around time for the results of 
the sputum culture test is 4 weeks due to the slow growth of M. tuberculosis on 
solid media (Palomino et al., 2007; Pingle et al., 2014).  
Specialized equipment and a level 3 biosafety laboratory facilities are also 
required to perform these procedures. 
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1.7.6 Molecular tests for TB Diagnosis  
Molecular diagnostic techniques are based on the detection of genomic, 
proteomic or metabolomic markers that are associated with the disease and can be 
used in diagnostics to indicate the presence of the disease state. It can also be 
used in prognosis to predict the outcome of a treatment.  
1.7.6.1 GeneXpert Test 
This is a recently developed rapid TB test (~2 hours), which detects M. 
tuberculosis DNA from a sputum sample (Walzl et al., 2015). GeneXpert is a 
cartridge-based, automated and rapid molecular diagnostic technique that 
performs sample processing and hemi-nested real-time polymerase chain reaction 
(PCR) analysis in a single, hands-free step. It is also used to determine genetic 
mutations in patients that have developed resistance to the antibiotic, rifampicin 
(Tang et al., 2017). Owing to the fact that, it can detect the DNA mutations that 
confers the M. tuberculosis resistance to the antibiotics, it is ideal for the rapid 
diagnosis of MDR-TB with a high sensitivity and specificity. The overall 
sensitivity, specificity, positive predictive value (PPV) and negative predictive 
value (NPV) values reported by Pandey and colleagues were 98.6 %, 100 %, 100 
% and 93.8 % (Pandey et al., 2017).  
When this test was launched in 2008, South Africa and India were among the 
countries chosen to perform clinical validation (Boehme and Nabeta, 2010). 
Despite bringing new hope for countries with high risk of TB, this test is very 
costly.  
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The unit cost of the test was estimated to be $9.98 (Pantoja, et al., 2015).  Also, 
the total capital cost (including instruments, additional space, security, and 
training) between 2011 to 2012 and 2016 to 2017, was estimated to be $20 
million (149 million ZAR). These also require an additional annual budget of 53 
to 57% or $48 to $70 million per year (Stevens, 2012). In addition, the 
GeneXpert test is also not reliable for individuals that are co-infected with HIV, 
and cannot differentiate between latent and active TB (Davis et al., 2013). They 
require highly trained personnel and a level 3 biosafety laboratory facilities 
(Pandey et al., 2017). Despite all these challenges, this test is currently the best 
performing TB diagnostic test and is used as the gold standard for the detection of 
antibiotic resistant TB. Compared to the conventional drug susceptibility tests, 
the GeneXpert test has a rapid turn-around time and is more accurate (Pandey et 
al., 2017).  
1.7.6.2 Line Probe Assays 
This test incorporates both the PCR and reverse hybridisation techniques to 
rapidly detect M. tuberculosis and the genetic mutations associated with 
antibiotic resistance. Just like the GeneXpert test, these tests provide rapid results 
but require biosafety level 3 precautions, and highly trained personnel. In 
addition, chances of contamination are also high because they employ open-tube 
formats, which expose the samples to the external environment. Ninan and 
colleagues demonstrated this when they detected M. tuberculosis DNA from dead 
bacteria yielding false positive results (Ninan et al., 2016).  
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These assays are also expensive to handle and to maintain. The assay costs 
$23.46 per sample. This is influenced by cost of consumables (60-80%), high 
labor costs ($3.46 per test) and overhead costs ($4.28 per test) due to the time 
involved and extensive laboratory facilities needed for test performance (Shah et 
al., 2013). 
1.7.7 Serological tests for TB 
Serodiagnostic tests are used to diagnose TB by detecting host antibodies against 
M. tuberculosis in the blood samples of infected hosts. These tests make use of 
Lateral Flow Immune Assays (LFIAs) to diagnose the infectious disease (Broger 
et al., 2017). However, antibody-based tests have low sensitivity and specificity 
resulting in false negative and false positive results. Patients can test positive in 
response to other organisms not necessarily M. tuberculosis. Nevertheless, these 
tests are cost effective compared to the above mentioned tests such as GeneXpert 
and Line Probe Assays.  
More than a million commercial serological tests were carried out in India every 
year, where each test cost up to $30 per patient (WHO, 2011). The cost of 
serological tests in India is conservatively estimated at $15 million per year 
(Steingart, et al., 2012). However, such countries have no published evidence to 
support their claims of accuracy and it was estimated that serological testing 
would result in 121,000 false-positive diagnoses, compared to the other TB tests 
endorsed by WHO. Research also suggested that for each additional smear-
negative TB case found by serology, more than six additional false-positive cases 
would be inappropriately diagnosed (WHO, 2011).  
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Therefore, despite the cost effectiveness of these tests, however, the WHO has 
cautioned against the use of them to diagnose active TB (Broger et al., 2017; 
WHO, 2011). 
1.8 Putative TB serum biomarkers  
Biomarkers are signature molecules or molecular indicators within body fluids 
and tissues that can be used to detect the presence of a particular biological 
condition or disease (Strimbu and Tavel, 2010). Biomarker discovery is the first 
step towards the development of rapid disease diagnostic systems.  
Recent efforts in the field of TB diagnostics have revealed the urgent need for 
biomarker-based assays that will enable more efficient, affordable, and accessible 
diagnostic tools.  Technologies such as DNA microarrays and proteomics have 
been used for biomarker discovery. However, despite the fact that huge volumes 
of data have been generated, less than 100 biomarkers have been validated for TB 
diagnosis by 2011 (Poste, 2011). Several biomarkers that were identified through 
proteomics have been validated clinically. Some of these biomarkers have 
already been used in the TST and IGRA tests.  
Proteomics technologies has demonstrated an improved efficiency for the 
identification of biomarkers that are present at very low concentrations in blood 
(Lee et al., 2015). Blood has been used for decades as the preferred biological 
fluid for the detection of disease conditions. It is a rich source of biomarkers that 
can be used to provide insights into pathological and physiological processes that 
are linked to disease states (Marko-Varga et al., 2005).  
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For this reason, the identification of biomarkers that can be used to detect TB at a 
very early stage (during latent infection) and during active TB will be of utmost 
importance, this would help prevent individuals from transmitting the deadly 
pathogen. This will in turn also hinder individuals from developing active TB and 
subsequently will foster the commencement of treatment programs, as 
recommended by WHO (Falzon et al., 2016). Hence research into the serum 
proteome has a good prospect of providing biomarkers associated with the 
pathophysiology of TB (Cho et al., 2006).  
The ease of accessibility of serum samples from patients makes it attractive to 
identify potential biomarkers that appear in the blood circulation after M. 
tuberculosis infection. The ease of identification of the potential biomarkers will 
in turn allow the development of less invasive diagnostic tests (Phillips et al., 
2010; Ray et al., 2011; Wallis et al., 2010). Several biomarkers for TB which 
includes Insulin-like growth factor binding protein 6 (IGFBP6), Apolipoprotein C 
(ApoC), C-reactive protein (CRP), Retinol-binding factor protein 4 (RBP4), 
Interferon-stimulated gene 15 (ISG15), Calcium-binding protein (S100A9), 
Rv1475c, Rv0578c PE-PGRS, Granzyme A (GrA) and Transgelin-2 (TAGLN2) 
have been discovered employing proteomics approaches (Mahmoudi et al., 2016; 
Young et al., 2014; Achkar et al., 2015).  
1.8.1 Insulin-like growth factor binding protein 6 (IGFBP6) 
IGFBP6 is an immune-stimulated protein released when the immune system 
detects the presence of bacterial infection (Achkar et al., 2015). IGFP6 is derived 
from the human bone marrow-derived mesenchymal stem cells (hMSCs).  
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Little is known about its role during M. tuberculosis infection, but had been 
shown to be up-regulated on the serum of patients with active TB (Le Bouc et al., 
1997).  
Patients who have respiratory diseases other than TB do not overexpress this 
protein, making it specific for M. tuberculosis infection in patients with active TB 
(Le Bouc et al., 1997). 
1.8.2 Interferon-stimulated gene 15 (ISG15) 
ISG15, also known as interferon-induced protein ifi-15k (IFI15), 
Immunodeficiency 38 (IMD38) or human C reactive protein (CRP), is an 
interferon-induced protein that is released in a homeostatic body state to foster 
communication between cells (Gagoski et al., 2016). When the host is invaded by 
M. tuberculosis, the infected macrophages induce an increase in the expression of 
the interferon-inducible proteins including ISG15 to enhance the release of the 
pro-inflammatory cytokines (Hare et al., 2015). This has been demonstrated 
using both in vitro and in vivo studies (Walters et al., 2013). Coincidentally, pro-
inflammatory cytokines such as the IFN-γ have been used in IGRA tests 
(described in Section 1.7.3). This therefore suggests that ISG15 can be a potential 
biomarker for M. tuberculosis infection.  
ISG15 is induced when the immune system detects the presence of bacteria. 
ISG15 is released by extracellular vesicles that are shed into the extracellular 
matrix due to the presence of the bacteria (Al-Nedawi et al., 2008; Walters et al., 
2013).  
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It was also shown that ISG15 expression, through the type I IFN signalling 
pathway (innate immunity), increases abundantly in M. tuberculosis-infected 
macrophages (Hare et al., 2015; Walters et al., 2013).  
1.8.3 Calcium binding protein (S100A9)  
S100A9 is a calcium-binding protein which play a role when the bacteria spread 
to the extra-pulmonary regions (Foell et al., 2007). S100A9 induces the activation 
and aggregation of the neutrophils promoting accumulation of pro-inflammatory 
chemokines and cytokines in the affected area.  
This was demonstrated in a mouse model of TB where the affected lung area was 
rich in leukocytes (Gopal et al., 2013). S100A9 is also a member of the SOD that 
plays a vital role in the protection against TB. It facilitates a balance between the 
ROS released in the presence of the pathogen and the antioxidants available 
within the affected region (Wang et al., 2013). In another study, S100A9 
expression levels were compared amongst PTB patients, patients with other 
pulmonary-related diseases such as pneumonia and lung cancer, and healthy 
volunteers (Rodríguez-Piñeiro et al., 2010). The study found that S100A9 serum 
levels were significantly higher in the PTB group than the other two groups 
suggesting that this protein may be a good biomarker to distinguish patients with 
TB from those that have other respiratory diseases (Rodríguez-Piñeiro et al., 
2010).  
1.8.4 Retinol-binding protein 4 (RBP4) 
RBP4 is an adipocyte secreted serum protein and a molecular marker for both 
diabetes and TB.  
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In obese and insulin resistance patients, RBP4 levels are increased in the blood 
circulation when compared to control individuals (Comucci et al., 2014). 
Increased levels of RBP4 were also found in patients with active TB infection.  
However, the expression level of the RBP4 reduces when active TB patients have 
chronic energy deficiency (Taslim et al., 2017). These findings contribute to the 
novelty of RBP4 as a prognostic biomarker for TB.  
1.8.5 Granzyme A (GrA) 
GrA is a tryptase (serine proteinase) that is up-regulated in patients with active 
TB infection (Lieberman, 2010). It is released by the natural killer (NK) cells and 
the cytotoxic granules of the T lymphocytes (CTLs) (Lieberman, 2003; Guggino 
et al., 2015).  GrA induces death of the cells infected with M. tuberculosis 
bacteria by activating an apoptosis-like death (Guggino et al., 2015). GrA induce 
cell death in a caspase-independent programmed cell death and use unique 
substrates and mediators. The caspase-dependent death is characterized by loss of 
cell membrane integrity, single-stranded DNA damage and mitochondrial 
dysfunction (Zhu et al., 2009).  GrA, in vitro cleave other proteins such as the 
nucleolin, IL 1β, fibronectin, type IV collagen, thrombin receptor, and pro-
urokinase-type plasminogen activator. Recent research reported that GrA can be 
used to discriminate latent TB from the active TB (Guggino et al., 2015; 
Mahmoudi et al., 2016).   
1.8.6 Transgelin-2 (TAGLN2) 
TAGLN2 was recently identified as a potential biomarker for both the latent and 
active TB infection.  
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TAGLN2 belongs to the family Transgelin (TAGLN) proteins, which are actin-
binding proteins of the calponin family, and are recognized for their rapid actin-
gelling properties (Assinder et al., 2009). The transgelin family is made up of 
three members named TAGLN1, 2 and 3. TAGLN1 is localized at the site of its 
expression in the smooth muscle cells, while TAGLN2 is highly expressed in TB-
infected and individuals co-infected with HIV (Stanier et al., 1998; Achkar et al., 
2015).  
It is also expressed in several cancer cells such as prostate, breast, colon and lung 
cancers (Stanier et al., 1998). TAGLN3 on the other hand, is highly expressed in 
the brain cells. TAGLN2 is highly expressed in TB-infected cells. It has five 
splice variants, with the fifth variant unable to translate to any protein. The rest of 
the variants are translated into proteins is not yet fully understood (Stanier et al., 
1998). The role of TAGLN2 in several infectious diseases is still unknown 
(Achkar et al., 2015).   
TAGLN2 was also reported to interact with the immunological synapse of the 
host in the presence of an attack either by a bacteria or any pathogen, and 
enhances T cell response by controlling actin stability at the immunological 
synapse (Na et al., 2016). This suggests its critical role and involvement in the 
immune response.  
In fact, in patients with active TB, TAGLN2 has been shown to be over-
expressed and can thus be used to accurately distinguish between active TB, 
latent TB and other respiratory diseases in both HIV
+
 and HIV
-
 individuals 
(Achkar et al., 2015).  
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TAGLN2 was also detected in almost all the TB patients across the globe 
including Asia, Africa, North and South America (Achkar et al., 2015). 
Therefore, TAGLN2 can potentially be used to detect TB not only at the early 
stages, but also TB individuals co-infected with HIV (Achkar et al., 2015).  
Most of the selected potential TB biomarkers listed above have roles that are 
relevant to the host’s response to TB, and can be considered for development of a 
rapid TB-diagnostic test.  
Thus detection of such serum biomarkers can be recognised as a practical 
approach not only for diagnosis, but for monitoring treatment efficacy and 
prognostic evaluation of patients with TB (Heo et al., 2009). These kinds of 
diagnostic tools would be a huge boost for developing countries that cannot 
afford expensive diagnostic laboratories.  
1.9 Aptamers 
Once suitable biomarker proteins have been identified, the next step in the 
development of rapid disease diagnostic systems is the identification of molecules 
that can bind to these proteins with high specificity and be used in the detection 
of these biomarker proteins. Antibodies have traditionally been used for this 
purpose, but aptamers are emerging as alternative and more superior molecules 
for this application. 
The term aptamer comes from two words, “aptus” which is Latin for “to fit”, and 
“meros” which is Greek for “part” or “region” (Ellington and Szostak, 1990; 
Robertson and Joyce, 1990; Tuerk and Gold, 1990).  
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Aptamers are synthetic single-stranded oligonucleotides (DNA, RNA) or peptide 
molecules that bind to a specific target (Darmostuk et al., 2014). They are shorter 
than 100 nucleotides (nt) in length and have an increased binding affinity and 
selectivity for specific targets, ranging from proteins to small molecules (Song et 
al., 2008). Their typical structural motifs include stems, internal loops, purine-
rich bulges, hairpin structures, pseudo-knots, kissing complexes, and G-
quadruplet structures (Chen and Yang, 2015).  
1.9.1 Comparison between aptamers and antibodies  
It was demonstrated that aptamers have an increased selectivity, specificity and 
affinity towards a variety of targets (from small drugs to whole cells) (Ozer et al., 
2014). In some cases aptamers have been able to discriminate between targets 
with only subtle structural differences (Wilson et al., 2001).  
Some of the features that make aptamers more appealing than antibodies for 
application in diagnostics are summarized in Table 1.3. They are considered to be 
superior to most targeting molecules, which include antibodies and targeting 
peptides. Aptamers can fold into three-dimensional structures that have a much 
higher affinity for binding its target compared to antibodies and other targeting 
ligands. The large-scale production of aptamers is more cost effective when 
compared to antibodies. Aptamers are tolerant to high temperatures, which imply 
that diagnostic devices using aptamers will have a longer shelf life.  
Most importantly, they can be easily modified for conjugation and biomedical 
application. 
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 Table 1. 3: Comparison of aptamers with antibodies (adapted from Chen and Yang, 2015). 
Feature  Antibody Aptamer 
Oriented 
immobilization 
Difficult through protein A/G  
 
Easy through various modifications  
Selection Limited to animal immunisation In vitro and in vitro selection under a 
variety of conditions 
Application target Proteins or haptens. Difficult for 
non-immunogenic or toxic targets 
Any targets from ions to whole cells, 
including non-immunogenic or toxic 
target 
Production  Time-consuming and costly Efficient with chemical synthesis at 
low costs  
Detection range Good  Better  
Modification Difficult and expensive to modify Cheap and easy to modified with other 
active groups in a large scale.  
Reusability Poor reusability due to irreversible 
conformational changes 
Good reusability through a reversible 
conformational switch 
Shelf life Short shelf life and require a 
continuous cold storage 
Long shelf life and does not require 
special storage conditions.   
Stability Sensitive to pH and temperature  Tolerant of pH and temperature  
 
1.10 Selection of aptamers using SELEX technology 
Unlike antibodies, aptamers can be synthesized in vitro by System Enrichment of 
Ligands by EXponential enrichment (SELEX). SELEX is one of the techniques 
used for synthesis and selection of aptamers used in diagnostics and therapeutics 
(Sun et al., 2014). SELEX is used for isolation and production of single stranded 
oligonucleotides (aptamers) that binds to specific targets with high affinity. 
SELEX have significantly improved over the years, with this technique 
producing aptamers with high specificity and selectivity. The aptamer structures 
can be modified pre- or post-SELEX process to prevent degradation by nucleases 
and to increase binding efficiency (Shigdar et al., 2013).  
The SELEX process is a series of steps that are repeated several times (8-25 
rounds) until the aptamers are highly enriched for the target molecule.  
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These steps include incubation of the random DNA library with the target (such 
as a biomarker protein), separation, amplification, single-strand generation, 
elution and purification as shown in Figure 1.2 (Chen et al., 2016; Tsao et al., 
2017).  
 
Figure 1. 2: SELEX overview.  Summary of the major steps involved in aptamer selection 
through SELEX, these include incubation of the target molecule with the random DNA library 
and isolation of target specific aptamers. Positive and negative selection steps are included to 
increase aptamers specificity (Chen et al., 2016). 
The selection of aptamers requires a serial incubation of the DNA libraries with 
its target to allow binding between the two molecules. The desired DNA 
sequences are obtained during SELEX by partitioning and amplification.  PCR 
amplification of the template is a critical tool to generate efficient dsDNA (Grote 
et al., 2002).  
Since the introduction of SELEX for aptamer selection in the 1990’s, (Ellington 
and Szostak, 1990; Robertson and Joyce, 1990; Tuerk and Gold, 1990), 
improvements have been made to either modify the existing method or to develop 
other strategies in-line with SELEX to rapidly and efficiently produce aptamers 
(Darmostuk et al., 2014; Lin et al., 2014; Yüce et al., 2015).  
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Several strategies are available that can efficiently isolate aptamers, these 
methods include cell-based SELEX, nitrocellulose (NC) membrane filtration-
based SELEX, affinity-based chromatography, capillary electrophoresis-based 
SELEX, microfluidic-based SELEX, magnetic bead-based SELEX and tailored-
SELEX (Lin et al., 2014; Vater et al., 2003).  
1.10.1 Nitrocellulose (NC) membrane filtration-based SELEX 
This strategy is based on the use of NC membrane for aptamer immobilisation. 
The target molecules are then incubated with the immobilized aptamers for a 
certain period of time before being eluted. The aptamers can be selected easily 
using this strategy due to their smaller sizes (Song et al., 2012). This strategy 
however generates false positive aptamers and with low sensitivity and specificity 
for the target molecule.  
This is because the generated aptamers could bind to the membrane with higher 
affinity than the proteins, resulting into a low sensitivity (Ozer et al., 2014). 
1.10.2 Affinity-based chromatography SELEX 
Aptamers against smaller molecules as well as proteins can be selected using this 
method. This method employs an affinity column, which has the target molecule 
immobilised on beads. The random nucleic acid library is incubated with the 
target molecules after which they are selected randomly by PCR.  
However, a significant drawback of this method is that it only targets molecules 
modified with affinity tags or functional groups (Wang et al., 2011; Song et al., 
2012).  
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This method is also less sensitive if the target lacks an affinity tag or a functional 
group is needed for capturing the beads. Also, enrichment of the aptamers 
towards the target is not guaranteed (Song et al., 2012). 
1.10.3 Tailored SELEX 
The tailored SELEX involves incubation of a randomised library (that lacks 
primer-binding regions) with the target molecule. Special adaptors are used to 
replace the primer binding regions in each SELEX round (Vater et al., 2003). 
This process produces aptamers that lack the primer regions that might have 
enhanced the binding to the target molecule. The method is time-consuming as it 
requires cloning of the pool (selected oligonucleotide) to the primer binding 
sequences after each selection step before the final round (Amano et al., 2017; 
Jarosch et al., 2006). 
1.10.4 Microfluidic-based SELEX  
The use of microfluidics in SELEX has reduced the time it takes to generate 
aptamers because SELEX is done and processed on a chip, and it can enhance 
selection efficiency on a small scale (Song et al., 2012). For example, the DNA 
aptamer specific for Neurotoxin type B was obtained after a single round of 
selection using the continuous flow magnetic activated chip based separation 
device (Song et al., 2012). However, the use of microfluidics is very costly, 
requires specialized instruments, and not readily available.  
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1.10.5 Neutral SELEX 
This method differs from the classical SELEX due to the exclusion of the 
selection step. The DNA/target complexes are PCR amplified at each and every 
step, and the sequences are selected afterwards (Amano et al., 2017). In this 
method, no sequences will be enriched for, as no target will be used during the 
selection process. Also, the sequences produced are less stable and have a high 
rate of mutation because the amplified products are used as the template for the 
next round (Chen and Yang, 2015). 
1.10.6 Capillary electrophoresis-based SELEX  
A mobility shift can be used to select aptamers from the mixture containing a 
target molecule and the random DNA library. This method uses a capillary 
electrophoresis system, allowing the aptamers to interact with targets without 
steric hindrance. Selection of aptamers can be achieved within a very few rounds 
(2-4 rounds) compared to other methods (Song et al., 2012).  
Unfortunately, enrichment of the aptamers towards the target is not guaranteed 
when using the capillary electrophoresis strategy (Song et al., 2012). 
1.10.7 Cell SELEX  
This process aims at searching for aptamers against a whole cell compared to the 
other SELEX methods whose primary target is a single small molecule. In this 
strategy, the targets can be combination of extracellular or transmembrane 
proteins or unique structures of the cell (Reinemann and Strehlitz, 2014).  
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This method however can result in false positivity due to the target location, and 
the specificity of the aptamers can be affected by the binding pockets of the target 
(Meyer et al., 2013).    
1.10.8 Magnetic bead-based SELEX  
This method starts with the incubation of a randomised DNA library with the 
target molecule. The target molecule has a tag on one of its end for binding to the 
tagged beads. An external magnet will then be used to attract the protein/DNA 
complexes captured on the beads to separate the bound from the unbound nucleic 
acids. This method can be employed to partition aptamers that have high affinity 
and selectivity towards target proteins (Chen et al., 2015; Gong et al., 2013; Lai 
and Hong, 2014; Stoltenburg et al., 2015; Xi et al., 2015). This strategy was 
selected for this study and it is described in detail in Section 2.2.16.1.  
1.11 Applications of Aptamers in the diagnosis of TB and other infectious 
organisms 
Aptamer-based LFIAs have been developed the past years to target various 
agents such as thrombin, cocaine, adenosine (Liu and Lu, 2006a, 2006b; Niu et 
al., 2014; Wang et al., 2007; Wei et al., 2007) and (1→3)-β-d-glucans (Low et 
al., 2009). Attempts were made to select aptamers against the whole M. 
tuberculosis bacterium (Chen et al., 2007) and proteins related to TB infections 
such as the MPT64 (Qin et al., 2009) and polyphosphate kinase 2 (PPK2) (Shum 
et al., 2011). However, these strategies were not effective as the aptamers lacked 
sensitivity against these proteins.  
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Other studies have also selected aptamers that can detect active TB from the 
sputum, aptamers were synthesized against the immuno-dominant antigens like 
the CFP-10, ESAT-6 and CFP-10-ESAT-6 heterodimer (Rotherham et al., 2012). 
Nevertheless, these aptamers have not been applied in any practical diagnostic 
tool due to lack of specificity and sensitivity. These proteins (CFP-10 and ESAT-
6) were used as targets by Mozioglu and colleagues (2016), the H37Ra (a M. 
tuberculosis protein) were used as targets in two different SELEX selection 
protocols (Mozioglu et al., 2016). However, the dissociation constants (Kd) for 
the aptamers identified in that study was less than the one obtained by Chen and 
co-workers when the team studied aptamers that recognize whole M. tuberculosis 
bacterium. The H37Rv aptamers were shown inhibit bacterial invasion of 
macrophages and decrease bacterial growth in the lungs. This study also 
demonstrated that aptamers can be used for diagnosis of TB and in development 
of anti-TB agents (Chen et al., 2012).  
1.12 Lateral flow assays for point of care rapid diagnosis  
Point of care (POC) diagnostics is defined as medical diagnostic testing at or near 
the time and place of patient care. POCs are mostly used as a screening rather 
than a diagnostic tool. These tests are cost effective and do not require expensive 
laboratory equipment or highly trained personnel to perform the test.  The test can 
be carried out at a primary healthcare facility and the test results are available 
immediately. This means that when a patient visit a primary healthcare facility, 
they can be tested and the results are available immediately. The patient can then 
be referred for additional testing or treatment immediately.  
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The results of these tests can normally be interpreted very easily, which means 
that POCs can even be used for self-testing. For these reasons POCs are ideal for 
low resource settings. Lateral Flow Assays (LFAs) are good examples of POCs.  
LFAs can be categorized into either lateral flow immunoassays (LFIAs) or 
nucleic acid lateral flow assay (NALFA) depending on their recognition elements 
used in the assay as indicated in Figure 1.3. The LFIAs make use of antibodies 
(such as the IgG) as recognition elements while the NALFAs use probes for the 
detection of amplicons, which are formed during PCR (Haridas and 
Thiruvengadam, 2014). The LFAs make use of membranes assembled in strips 
with antibodies mounted on them for the detection of antigens. The test results 
are obtained within few minutes, generally 5-30 min (Koczula and Gallotta, 
2016).  These tests are gaining interest as more companies are inspired to develop 
lateral flow devices that will provide rapid diagnosis for infectious diseases such 
TB (Koczula and Gallotta, 2016).   
 
Figure 1. 3: Different types of LFAs employed in the diagnosis of molecules in complex 
biological samples (Koczula and Gallotta, 2016). 
 
More than 100 companies worldwide have developed screening assays over the 
past thirty years.  
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Their annual growth rate was compounded at 7 %, with the global market of this 
technology estimated to reach $4675 million by 2020 (Koczula and Gallotta, 
2016).  
The antibody-based platform has been widely used for the direct detection of 
antigens present in patients’ samples. The stability of antibodies is a major 
challenge in the development of LFAs (Chen and Yang, 2015). The current TB 
diagnostic assays have limited sensitivity (43 – 71 %) and show inconsistency (84 
– 100 %) (Fu and Xie, 2011; Steingart et al., 2011). The introduction of a rapid, 
cost-effective, and sensitive POC diagnostic device that can detect the TB at an 
early stage of infection, can differentiate between latent and active TB, and can 
differentiate between TB and other pulmonary diseases will significantly improve 
treatment outcomes for many TB patients. The application of aptamers that can 
recognize serum biomarkers can lead to the development of such POC diagnostic 
devices. 
1.13 Aims and objectives of the study 
1.13.1 Aims of the study:  
1. To identify and select potential serum TB biomarkers from published studies 
(proteomics studies). 
2. To generate aptamers against the selected biomarkers using magnetic-bead 
based SELEX. 
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1.13.2 Objectives of the study: 
1. Identify potential serum biomarkers for TB. 
2. Clone, express and purify TB biomarker protein through recombinant DNA 
technology. 
3. Use magnetic-bead based SELEX for selection of aptamers against the 
biomarker proteins. 
4. Study binding efficiency of aptamers to the target proteins. 
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CHAPTER 2 
MATERIALS AND METHODS 
2.1 Materials and buffers 
 
        Table 2. 1: Reagents and their suppliers 
 
Reagent 
Supplier 
Absolute Ethanol Kimix Chemicals (South Africa, SA) 
40 % Acrylamide Bis Solution (37:5:1) Bio–Rad (United States of America, USA)  
Certified low range ultra-agarose 
Bovine serum albumin (BSA)  
Bromophenol blue 
Glycine 
Phosphate buffered saline (PBS) pH 7.4 ready mix 
Sodium Acetate 
Sodium Azide  
N,N,N',N'-tetramethylethane-1,2-diamine 
(TEMED) 
 
 
 
Sigma Aldrich Co. (USA) 
Ammonium persulfate 
Boric acid 
Ethylene-diamine-tetra-acetic acid (EDTA) 
Glycerol 
Magnesium Chloride  
Potassium Chloride 
Sodium Hydroxide 
Tris(hydroxymethyl)aminomethane 
 
 
 
Merck (Pty) Ltd (SA) 
Deoxynucleotide mix 
Ethidium bromide 
Promega (USA) 
DNA loading dye  Inqaba Biotechnical industries (Pty) Ltd 
(Inqaba® biotech, SA) 
DNA oligonucleotides Integrated DNA Technologies (IDT, USA) 
Ethanolamine-HCL  
1-Ethyl-3-(3-dimethylaminopropyl)-carbodiimide 
(EDC)  
N-hydroxysuccinimide (NHS) 
GE Healthcare (Pty) Ltd (SA) 
Gel Red Stain Biotium Inc (SA) 
HC 1000M SPR chips   
4-2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES) buffered solution with sodium chloride 
Xantech bioanalytics (Germany) 
Human Serum Albumin (HSA) Roche Diagnostics (SA)  
Transcriptor First Strand cDNA Synthesis Kit 
Kapa Taq ready mix Kapabiosystems (Pty) Ltd (SA) 
Magnesium Acetate 
Potassium Acetate 
T7 gene 6 Exonuclease with Lambda Exonuclease  
New England Biolabs (United Kingdom, 
UK) 
Nickel-NTA coated magnetic beads  
SiMAG-IDA/Nickel beads 
Chemicell GmbH (Germany) 
O’GeneRuler® 100bp Plus DNA ladder Life Technologies (Pty) Ltd (SA) 
O’GeneRuler® 1kbp Plus DNA ladder Fermentas Life Sciences (Canada) 
Velocity taq polymerase kit Bioline (UK) 
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              Table 2. 2: Equipment and their suppliers 
Equipment Supplier 
PowerPac™ Basic Power Supply Bio–Rad (USA) 
Eppendorf Thermomixer comfort Merck (Pty) Ltd (SA) 
Dynamag®-2 Magnetic Particle concentrator  
Shaker Eppendorf 5414 
Water-Jacketed CO2 Incubators  
 
Thermo Scientific (SA) 
Eppendorf® Microcentrifuge 5415 DJB Labcare (UK) 
GeneAmp® PCR System 2700 Applied Biosciences (SA) 
ProteOn XPR36  Rhodes University (SA) 
Qubit® 2.0 Fluorometer Invitrogen by Life technologies (USA) 
 
Stuart Block Heater Stuart Scientific (UK) 
UVP BioSpectrum® Imaging System  The Scientific group (Pty) Ltd (SA)  
 
           
              Table 2. 3: Composition of buffers used in the study 
Buffers Composition 
SELEX buffer PBS with 1.5 mM Mg2+ pH 7.4. 
   
   
EMSA loading buffer  60 mM Pottasium chloride, 10mM Tris (pH 7.6), 5 % 
Glycerol, 0.01 % Xylene cyanol,  
0.01 % Bromophenol blue. 
  
TBE buffer  0.089 M Tris, 0.089 M Boric acid, 0.002 M EDTA  
  
TE buffer  10 mM Tris (pH 8.0), 1 mM EDTA. 
  
Sample buffer 0.5 M Tris-HCl pH 6.8, glycerol (100 %), 0.2 mL of β 
mercaptoethanol, 0.01 g of bromophenol Blue 
and 0.2 g of SDS. 
  
1 X SDS Running buffer 3.03g Tris (250 mM), 14.4g Glycine (1.92M) and 10g 
SDS (1 %). 
Coomasie stain solution 50 % ethanol, 10 % acetic acid and 0.25 % brilliant blue 
R-250 
De-stain solution 16.5 % ethanol and 5 % acetic acid 
Lysis buffer 50 mM potassium phosphate, pH 7.8, 400 mM NaCl, 100 
mM KCl, 10 % glycerol, 0.5 % Triton X-100 and 10mM 
imidazole. 
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2.2 Methodology 
2.2.1 In silico identification and selection of serum TB biomarkers 
Intensive literature mining using various search engines (such as Google scholar, 
PubMed, UniProtKB, SciFinder, NCBI gene bank, RefSeq, protein data bank, 
PDB) was performed to identify TB serum biomarkers. The potential biomarkers 
were selected from recent TB proteomics case studies, published between 2014 
and 2017. The biomarkers were selected based on the following criteria:  
i. The biomarkers must be expressed or shed in the serum samples of TB-
infected patients. 
ii. The biomarkers must have been identified by more than one independent 
study. 
iii. They must be able to discriminate between the active TB and the latently 
infected patients. 
iv. Interest is on the proteins that have not been previously used for 
development of aptamer-based TB diagnostics. 
v. Biomarkers must be expressed through recombinant DNA technology with 
ease.  
vi. Biomarkers must be specific to M. tb strain, and be able to discriminate 
individuals infected with the other MTBC strains.  
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2.2.2 RNA extraction   
Total RNA was extracted from several human cancer (SKOV-3, CaOV-3, 
LNCaP, MCF-7) and normal (KMST-6 and MCF-12A) cell lines, the cells were 
shown to encode the genes of selected TB biomarkers.  The cells were cultured in 
T-25 (25 cm
2
) flasks until ≃70 % confluent. The cells were obtained from 
DST/Mintek NIC laboratory (Biotechnology Department, UWC).  
Total RNA was extracted from the cells using the High Pure RNA Isolation Kit 
(Roche Diagnostics) according to manufacturer’s instructions. Briefly, the cells 
were lysed by adding 400 μL Lysis buffer and vortexed for 15 seconds.  The 
lysate was transferred to High Pure Filter tube, followed by addition of 90 μL 
DNase incubation buffer and 10 μL DNase enzyme. The tubes were centrifuged 
for 45 seconds. The pellets were washed first with 500 μL wash buffer I then 500 
μL wash buffer II. RNA was eluted with 50 μL elution buffer. The RNA was 
quantified using the Qubit® 2.0 Fluorometer (Invitrogen) following the 
manufacturer’s instructions. The RNA integrity was evaluated by electrophoresis 
on a 1 % agarose gel. The gel was visualised and the images were captured using 
the UVP BioSpectrum® Imaging System (The Scientific group (Pty) Ltd).  
2.2.3 cDNA synthesis 
The cDNA was synthesised using the Transcriptor First Strand cDNA Synthesis 
Kit (Roche Diagnostics) in accordance with the instructions set by the 
manufacturer. One μg of the total RNA was added to the solution containing the 
Random Hexamer Primer and the volume was adjusted to 13 μL using nuclease-
free water.  
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The RNA secondary structures were denatured by heating the sample for 10 min 
at 65 
0
C. The tube containing the template-primer mix was cooled immediately 
on ice, followed by addition of 4 μL Transcriptor Reverse Transcriptase Reaction 
buffer, 0.5 μL Protector RNase Inhibitor, 2 μL Deoxynucleotide Mix and 0.5 μL 
Transcriptor Reverse Transcriptase. The reaction mixture was mixed gently and 
incubated at 50 
0
C for 1 hour. The enzyme was deactivated at 85 
0
C for 5 min. 
The synthesised cDNA was quantified by the Qubit® 2.0 Fluorometer and stored 
at -20 
0
C until required for downstream applications.   
2.2.4 Primer design 
The DNA sequences for the genes encoding the selected biomarkers were 
obtained from NCBI gene bank. The sequences were used to design PCR primers 
for the genes. The primers were designed manually and confirmed using 
Primer3Plus software 
(http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi).  
The primer sequences are shown in Table 2.4. The CACC sequence was 
incorporated into the forward primers for cloning in the Champion™ pET100 
Directional TOPO® vector (TOPO
R 
vector).  
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           Table 2. 4: Primers designed for the TB genes  
Gene Name   Primer Sequence 
ISG15 F
+
 5’CACCATGGGCTGGGACCTGACGGTGAAGATG’3 
R
- 5’GCTCCGCCCGCCAGGCTC’3  
IGFBP6 F
+ 5’CACCATGACCCCCCACAGGCTGC’3 
R
- 5’GCCGCTACTCCCAGTGGGGC 
S100A9 F
+
 5’CACCATGACTTGCAAAATGTCGCAGCTGGAAC’3 
R
-
 5’GGGGGTGCCCTCCCCGAG’3 
GrA F+ 5’CACCATGGCCAACTGTGAGCGTACCTTCATTG’3 
R
- 5’TTCATAGATCCAGTTCTGAGCACAGCTC’3 
RBP4 F
+
 5’CACCATGAAGTGGGTGTGGGCGCTCTTG’3 
R
-
 5’CAAAAGGTTTCTTTCTGATCTGCCATCG’3 
TAGLN2 F
+
 5’CACCATGGCCAACAGGGGACCTGCATATG’ 
R
-
 5’TTAACCATTCGTGGGAGGGCAGGG’3 
Notes: F
+
- Forward primer,R
-
 - Reverse primer, ISG15 – Interferon-stimulated gene 15, IGFBP6 
– Insulin-like growth factor binding protein 6, S100A9 – Calcium binding protein, GrA – 
Granzyme A, RBP4 – Retinol binding protein 4, TAGLN2 – Transgelin-2.   
 
 
2.2.5 PCR amplification of genes encoding TB biomarkers 
The genes of interest were amplified from the cDNA synthesized in Section 2.2.3 
as the template. A thermostable, proofreading DNA polymerase (velocity DNA 
polymerase) was used to produce blunt-end PCR products compatible for cloning 
in the Champion™ pET100 Directional TOPO® vector. The PCR conditions 
were as follows:  
                   Step 1: initial activation of the Taq polymerase at 95 
0
C for 3 min 
                 Step 2: denaturation of the template at 95 
0
C for 30 seconds 
                 Step 3: annealing of the dNTPs to the template at 66.9 
0
C 
                 Step 4: an extension of the template at 72 
0
C for 30 seconds 
                 Step 5: final elongation at 72 
0
C for 5 min 
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Steps 2-4 cycles were repeated 30 times. Gradient PCR was performed for all the 
genes (IGFBP6, ISG15, S100A9, GrA, RBP4 and TAGLN2) to determine the 
optimum PCR conditions.  
The genes were all observed to anneal at different temperatures ranging from 55 
0
C to 72 
0
C, however 66.9 
0
C was chosen for all the genes.  
2.2.6 Purification of PCR-products 
The PCR products were cleaned and purified using the GeneJet
TM
 Gel Extraction 
Kit (Fermentas) following manufacturer’s instructions. All the purification steps 
were carried out at room temperature (25 
0
C), and all the centrifugations were 
carried out in a table-top microcentrifuge at 16 000 rpm. For every 100 μL of the 
PCR reaction mixture, 100 μL of binding buffer was added. The solution was 
thoroughly mixed and the colour of the solution was checked. A yellow colour 
indicated an optimal pH for DNA binding, an orange or violet colour required 
addition of 10 μL 3M sodium acetate solution (pH 5.2). For genes <500 bp such 
as ISG15, S100A9 and GrA, 100 % isopropanol was also added at a ratio of 1:2 
(i.e, 100 μL of isopropanol, 100 μL of PCR mixture, and 100 μL of binding 
buffer) and the solution was mixed thoroughly. The solution was then transferred 
to the GeneJET purification column and centrifuged for 45 seconds. The flow-
through was discarded; the column was washed with 700 μL wash buffer and 
centrifuged for 45 seconds. The flow-through was discarded, the purification 
column was centrifuged for an additional 1 min to remove residual wash buffer. 
The column was transferred into a clean 1.5 mL microcentrifuge tube, 500 μL of 
elution buffer was added to the column and the tube was centrifuged for 1 min. 
http://etd.uwc.ac.za/
45 
 
The purified PCR products were quantified using the Qubit
TM
 fluorometer and 
stored at -20 
0
C until further analysis.  
2.2.7 Quantification of the DNA samples using the Qubit
TM
 fluorometer 
DNA was quantified using the Qubit® 2.0 Fluorometer following manufacturer’s 
instructions. A working solution was prepared as follows; (1 µL x n) of Quanti-iT 
Reagent was combined with (199 µL x n) Quant-iT buffer; where n is the number 
of samples to be quantified. 198 µL of the working solution was aliquoted into 
0.5 mL tubes and 2 µL of the sample of interest (PCR products) was added. The 
mixture was vortexed carefully and incubated for 2 min at 25 
0
C. The 
concentration of the samples was read using Qubit™ fluorometer. 
2.2.8 Cloning of genes into TOPO vector 
The TOPO
R
 Cloning Reaction was performed as described by the manufacturer, 
the reaction was prepared as summarised in Table 2.5. For optimal results 0.5:1 to 
2:1 molar ratio of PCR product to TOPO
R 
vector was used, the concentration of 
the insert was calculated using the formula below:  
 
ng of vector x kb size of insert
kb size of vector
x molar ratio of  
insert
vector
= ng of insert 
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Table 2. 5: Reaction mixture for cloning of selected genes in the TOPO
R
 vector 
Reagent Volume (µL) Concentration (M) 
PCR product 1  1 
NaCl and MgCl2 1 1.2 and 0.06 
   
Sterile water  3 - 
TOPO
R
 vector (20 ng)  1        1 
Total volume 6  
 
The reagents were mixed gently and incubated at 25 
0
C for 5 min and then placed 
on ice. The ligation mixture was used to transform One Shot
R
 TOP10 chemically 
competent Escherichia (E.) coli cells. Briefly, 3 μL of the TOPO Cloning 
reaction was added into a vial of One Shot
R
 TOP10 E. coli cells and mixed 
gently. The mixture was incubated on ice for 30 min. The cells were then heat-
shocked in a 42 °C water bath for 30 seconds and the tube was immediately 
transferred to ice. Super optimal broth (SOC) medium (250 μL) was added to the 
tube and incubated at 37 °C for 3 hours with shaking (300 rpm). The bacterial 
culture was spread on a pre-warmed selective agar plate (containing 100 μg/mL 
ampicillin) and incubated overnight at 37 °C.  
2.2.9 Colony PCR screening 
Following transformations, the positive clones were screened for the presence of 
inserts using the gene-specific primers and vector specific primers. The reaction 
mixture was prepared as summarised in the Table 2.6. 
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              Table 2. 6: Reaction mixture for colony PCR screening 
Reagents Volume (μL) Final Concentration 
Template DNA Scratch of colonies - 
10 μM Gene specific primers - 0.1 μM 
   
2x Kapa Taq Extra HotStart Ready 
MasterMix 
- 1 X 
50 mM MgCl2 - 3 mM 
   
25 mg/mL BSA - 0.5 mg/mL  
   
Final volume adjusted with nuclease-
free water 
10 μL  
   
 
The inserts were amplified using the conditions described in Section 2.2.5. 
The colony PCR products were electrophoresed on a 1.2 % ultra-low agarose 
gel. The gel was viewed and imaged on a UVP BioSpectrum® Imaging 
System. 
2.2.10 DNA plasmid extraction  
Positive colonies were inoculated in 10 mL ampicillin positive (Amp
+
) 
Lysogeny Broth (LB) and grown overnight at 37 
0
C while shaking. Glycerol 
stocks of the bacterial cultures were prepared and stored at -80 
0
C. The rest of 
the bacterial cultures were used to isolate plasmid DNA using the Wizard Plus 
SV minipreps DNA Purification Systems (Promega) following manufacturer’s 
instructions. The cultures were centrifuged at a maximum speed in a 
microcentrifuge for 5 min.  
The pellets were thoroughly resuspended with 250 μL of Cell Resuspension 
Solution, followed by addition of same amount of Cell Lysis Solution. The 
solutions were mixed by inversion of the tubes.  
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Then 10 μL of Alkaline Protease Solution was added and mixed by inversion. 
The samples were incubated for 10 min at 25 
0
C, followed by the addition of 
350 μL of Neutralization Solution and mixed by inversion. The samples were 
centrifuged at top speed for 15 min, the cleared lysate was decanted into the 
spin column and the samples were centrifuged at top speed for 3 min. About 
750 μL of Wash Solution was added and this was followed by centrifugation 
at top speed for 3 min, this step was repeated using 250 μL of the Wash 
Solution. The plasmid DNA samples were electrophoresed on a 1.2 % ultra-
low agarose gel and the gel was analyzed on a UVP BioSpectrum® Imaging 
System. The DNA was stored -20 
0
C. 
2.2.11 DNA sequence analysis 
The respective glycerol stocks were streaked on amplicillin containing agar 
plates.  The plates were subsequently incubated at 37 
0
C for 16 hours and sent 
to Inqaba® biotech for sequence analysis. The analysis was done using the 
universal T7 primers (sequences: Forward primer 5'-TAA TAC GAC TCA 
CTA TAG GG-3'; Reverse primer 5´-TAG TTA TTG CTC AGC GGT GG-
3´). The resultant raw DNA sequence data was uploaded and analysed in 
Basic alignment tool (BLAST)  
(http://www.mbio.ncsu.edu/BioEdit/bioedit.html).  
2.2.12 Transformation of the BL21 Star™ (DE3) One Shot® Cells  
Upon confirmation of successful cloning, the BL21 Star™ (DE3) E. coli 
strain was used to express the TB-biomarkers.  
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Transformation of the BL21 Star™ (DE3) One Shot® Cells followed a 
similar protocol described in Section 2.2.8. The entire transformation reaction 
was streaked in a LB agar plates containing 100 μg/ mL ampicillin and 1 % 
glucose and grown overnight at 25 °C. 
2.2.13 Pilot protein expression of the TB biomarker  
Several positive colonies were cultured in 10 mL LB containing 100 μg/ mL 
ampicillin and 1 % glucose overnight. The cultures were diluted 1: 10 with 
fresh LB and grown for three hours at 25 °C with shaking at 300 rpm until the 
sample reached OD600nm of 0.5 - 0.8. The cultures were then split into two 5 
mL cultures, 1 mM IPTG was added to one of the cultures and the other 
sample was uninduced. The cultures were further cultured under the same 
conditions for ~16 hours. The following day, the culture was centrifuged at 
maximum speed for 5 min, the cell pellets were analysed for the expression of 
the proteins by sodium dodecyl sulphate polyacrylamide gel (SDS-PAGE). 
2.2.13.1 Screening of protein expression by SDS-PAGE  
The samples obtained from the pilot expression (2.2.13) were resuspended in 10 
mL PBS, then 80 μL of the samples were mixed in a 1:1 ratio with 2X laemmli 
sample buffer.  
The samples were boiled for 5 min at 95
0
C and pulse spun, both the pellet and the 
supernatant (10 μL) were resolved by 15 % SDS-PAGE. The components for 
making the stacking and the separating gels are shown in the Table 2.7. 
 
http://etd.uwc.ac.za/
50 
 
Table 2. 7: Reaction mixture for SDS-PAGE screening of the proteins 
Reagents 12 % Separating Gel 5 % Stacking gel 
0.5M Tris-Cl pH 6.8 - 750 µL   
1.5M Tris-Cl, pH 8.8 2.5 mL  - 
10 % SDS 0.2 mL  60 µL 
Acrylamide/Bis (40 %) 3.76 mL  372 µL 
10 % Ammonium persulfate 
(APS) 
0.1 mL 30 µL 
TEMED 10 µL 10 µL   
Water 3.76 mL 3 mL 
 
The gel was electrophoresed in 1 X SDS Running buffer at 90 V for 30 min then 
the voltage was adjusted to 150 V and continued to run for 60 – 90 min. The gel 
was stained with coomassie stain for 30 min and de-stained overnight. The gel 
was visualised and the images were captured using the UVP BioSpectrum® 
Imaging System and Canon CanoScan LiDE 120 electronic scanner. The 
remaining samples were stored at -20 °C. 
2.2.13.2 Analysis of recombinant protein solubility 
The pellet samples were resuspended in 500 μL Lysis buffer. The cells were 
subjected to freezing and thawing cycles in dry ice and at 42 °C, three times. The 
cells were then sonicated briefly in a three cycles at 10 second interval. The 
samples were centrifuged at 16 000 rpm for 5 min. The supernatant was 
transferred to a fresh microcentrifuge tube. An equivalent amount of both 
supernatant and the pellet was mixed with 2X SDS-sample buffer, the mixture 
was boiled for 5 min at 95 °C. The samples (10 μL supernatant and 5 μL pellet) 
were loaded onto a 15 % SDS-PAGE and electrophoresed. The gel was stained 
and destained as above and imaged with a UVP BioSpectrum® Imaging System. 
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2.2.14 Large-scale expression of the TB biomarkers 
The protein was expressed as described in Section 2.2.13, with few adjustments. 
The inoculation culture and the temperature were increased to 2 L and 37 
0
C, 
respectively.  
2.2.15 Protein purification   
The His-tagged samples were purified in a column by nickel-bead affinity 
chromatography and analysed by SDS-PAGE. They were used to screen for 
protein expression as well as protein solubility. The purified proteins were 
quantified by the Qubit
TM
.  
The purified samples were concentrated in a small-sized concentrator before 
dialysis in PBS. The dialysed samples were lyophilized and stored at 4 
0
C until 
further downstream applications.  
2.2.16 Selection of Aptamers for TB biomarkers 
2.2.16.1 Magnetic-bead based SELEX  
TAGLN2 was used for aptamer selection by Magnetic-bead based SELEX 
following the protocol described in the Figure 2.1. 
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Figure 2. 1: An overview of the magnetic bead-based SELEX. A random library was incubated 
with the target recombinant protein for 30min. The bound and unbound pools were separated 
using magnetic beads, and then amplified by PCR. The process was repeated 8 - 15 times. The 
final pool was characterized and sent for sequence analysis (Kurt, 2013). 
 
2.2.16.2 Preparation of DNA library for SELEX  
The DNA aptamer library was a gift from Prof C.K O’Sullivan (Universitat 
Rovira I Virgili, Spain). The library was initially purchased from IDT 
Technologies. The library was made up of random 10
13
 to 10
15 
oligonucleotide 
sequences. Each aptamer in the library contained a 53 bp variable/random region 
(to which a target sequence can bind) that was flanked by 21 and 23 bp 
conserved/fixed primer sequence as shown in Figure 2.2.  
 
Figure 2. 2: The oligonucleotide aptamer library was made up of the random DNA region 
flanked by target primer sequences. 
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The library was prepared by diluting 300 pmoL of DNA library in 100 μL of 1X 
SELEX buffer (PBS, pH 7.4; 1.5 mM MgCl2).  The DNA library was denatured 
at 95 °C for 5 min, followed by gradual cooling of 10 °C every 1 min, until it 
reached 25 °C. The denatured DNA library was kept at 25 °C prior to incubation 
with the purified recombinant protein. The DNA library and aptamer sequences 
used for SELEX are summarized in the Table 2.8. 
Table 2. 8: SELEX DNA library and aptamer sequences and their suppliers 
Name Sequence Supplier 
SELEX library  5’-AGC TCC AGA AGA TAA ATT ACA GG- 
(53N)- CAA CTA GGA TAC TAT GAC CCC-3’  
IDT Technologies 
5’phosphorothi
ate modified  
aptamer 
F
+
 5’-A*GCTCCAGAAGATAAATTACAGG-3’  
R
-
 5’-GGGGTCATAGTATCCTAGTTG-3’ 
Whitehead Scientific 
(Pty) Ltd (South Africa) 
Apt_1 (Full 
length region, 
FL) 
5’AGCTCCAGAAGATAAATTACAGGTTGAAT
GGTCAGAGGATTGCATGGACTGCCGGTGG
GTGGGTGGGGGGTGGCATCAACTAGGATA
CTATGACCCC3’ 
 
 
 
 
 
 
 
 
 
 
 
Inqaba Biotechnical 
industries (Pty) Ltd 
(South Africa) 
 
 
Apt_1 
(Truncated 
Region, TR) 
5’TTGAATGGTCAGAGGATTGCATGGACTG
CCGGTGGGTGGGTGGGGGGTGGCAT3’  
 
Apt_2 (FL) 5’AGCTCCAGAAGATAAATTACAGGATTTAT
AAGGGTGGCTAGTTAATAGGGGATGGGGT
GGGTGGTTGTGGGTTCGTCAACTAGGATAC
TATGACCCC3’ 
 
Apt_2 (TR) 5’ATTTATAAGGGTGGCTAGTTAATAGGGG
ATGGGGTGGGTGGTTGTGGGTTCGT’3 
Apt_7 (FL)  5’AGCTCCAGAAGATAAATTACAGGGGTGGG
TGGGAGGGTTTTTGTAGTTAGAGGAAGGG
GAGCTGTGGTCTTAACACCAACTAGGATAC
TATGACCCC’3 
 
Apt_7 (TR) 5’GGTGGGTGGGAGGGTTTTTGTAGTTAGA
GGAAGGGGAGCTGTGGTCTTAACAC3’ 
Apt_9 (FL) 5’AGCTCCAGAAGATAAATTACAGGCAGTAA
TAGAGGGGAGGTATGTGTGTTGCTTAATT
GTGGGTGGGCGGGTGGAACAACTAGGATA
CTATGACCCC3’  
Apt_9 (TR) 5’CAGTAATAGAGGGGAGGTATGTGTGTTG
CTTAATTGTGGGTGGGCGGGTGGAA3’ 
T7 Primers  F
+
 5´TAATACGACTCACTATAGGG3´ (327pMol) 
R
- 5’TAGTTATTGCTCAGCGGTGG3’ (325pMol) 
Invitrogen  
*Indicates the phosphorothioate modification; F
+
 = forward primer; R
- 
= reverse primer 
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2.2.16.3 Selection of TAGLN2 aptamers by magnetic bead-based SELEX 
The recombinant histidine-tagged TAGLN2 protein was diluted in deionized 
water to a concentration of 30 pmoL. The first round of SELEX involved 
incubation of the prepared DNA library with the 30 pmoL protein target (at a 
ratio of 10:1 library DNA to target) for 30 min 25 °C with shaking at 500 rpm. 
SiMAG/Nickel beads (Chemicell GmbH, Germany) were added to the DNA 
library-protein mixture. About 0.15 mg of the SiMAG-IDA-Nickel beads was 
incubated for 30 min at 25 °C with the DNA library-protein mixture. To remove 
unbound DNA, the immobilised DNA library-protein mixture was placed on a 
magnet for 2 min. The bead complex containing the bound DNA library-protein 
was then washed by re-suspending the bead pellet in 100 µL 1X SELEX buffer, 
after which the beads were again captured using the magnet. This was repeated 
three times. After the 3
rd
 wash the bead mixture was re-suspended in 25 µL 
nuclease-free water. The re-suspended DNA (in a complex mixture with beads 
and protein) was used as template in a Pilot PCR. This constituted the positive 
SELEX. The steps employed for all the rounds are summarized in the Table 2.9. 
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Table 2. 9: Steps for isolation of aptamers using in vitro SELEX  
SELEX 
round 
Negative SELEX Counter SELEX Positive SELEX 
Round 1 - - 300 pmol DNA 
library + 30 pmol 
TAGLN2 protein 
(30 min) 
Round 2 – 4 Purified ssDNA + SiMAG-
IDA-Ni beads 
(30 min; 500 rpm) 
- Unbound ssDNA 
+ 30 pmol 
TAGLN2 protein 
(30 min; 500 rpm) 
Round 5 - 7 Purified ssDNA + SiMAG-
IDA-Ni beads 
(20 min; 500 rpm) 
- Unbound ssDNA 
+ 15 pmol 
TAGLN2 protein 
(20 min; 500 rpm) 
Round 8 - 14 Purified ssDNA + SiMAG-
IDA-Ni beads  
(20 min; 500 rpm) 
Unbound ssDNA + 15 
pmol HSA 10 min; 15 
pmol TAGLN2 protein 
(10 min) 
Counter SELEX; 
(20 min; 500 rpm) 
 
2.2.16.4 Negative SELEX to increase aptamers specificity  
To ensure specificity of the aptamers selected against the target protein, SELEX 
was repeated 14 times. The resultant PCR products were analysed on a 3 % 
agarose gel and then used for the next round of SELEX and the ssDNA was 
stored at -20 
0
C until further analysis. After the first round, a negative selection 
step was introduced to remove DNA that was bound non-specifically. This was 
done by incubating the eluted DNA with SiMAG/ Glu beads in binding buffer for 
30 min at 25 °C under the conditions mentioned earlier (Section 2.2.16.3). The 
unbound DNA was used as a template for the next cycle of SELEX. The bound 
sample was then used as the template for the pilot PCR. 
The pilot PCR was used to determine the optimal number of cycles for PCR 
scale-up. The lib-protein-bead complex was added to the master mix and 
subjected to PCR conditions as described in Section 2.2.5.  
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The samples were removed manually from the PCR at cycle numbers 5, 10, 15, 
20 and 25 to obtain the optimal number of cycles that produces the best products. 
The samples (10 µL) were analyzed on a 3 % agarose gel and viewed on a UVP 
BioSpectrum® Imaging System. 
2.2.16.5 Scaled-up PCR 
The optimum number of cycle that produced the distinct band without any non-
specificity (determined in Section 2.2.16.4) was used to scale up the PCR 
reaction volume to 100 μL prior to enzyme digestion for ssDNA production. The 
amplified products were subjected to agarose gel electrophoresis on a 3 % 
agarose gel and then analysed by UVP BioSpectrum® Imaging System.  
2.2.16.6 Counter SELEX 
Counter SELEX was introduced after the seventh rounds of selection to increase 
the specificity of the sequences that bind to the target (protein of interest). The 
supernatant containing the unbound DNA was incubated with the protein of 
interest (15 pmoL) for 10 min, at 25 
0
C, while shaking at 500 rpm. Human serum 
albumin (HSA) was selected as the counter protein. HSA was added at a final 
concentration of 15 pmoL and incubated for a further 10 min, at 25 
0
C, while 
shaking at 500 rpm. About 0.15 mg of the SiMAG-IDA-Nickel beads was added 
to HSA/lib complex, the bound bead complex was isolated and resuspended in 20 
μL of PCR grade water. The samples (10 µL) were analyze on a 3 % agarose gel 
and viewed on UVP BioSpectrum® Imaging System. 
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2.2.16.7 T7 enzymatic digestion 
Degradation of the unmodified dsDNA strands was done using a strand-specific 
enzyme, the T7 Gene 6 Exonuclease. The PCR amplicons were incubated with 1 
X NEBuffer 4 and 40 units of the enzyme for 6 hours at 25 °C. This was followed 
by enzyme inactivation at 65 °C for 5 min. The samples were loaded onto the 
agarose gel for electrophoresis and viewed by UVP BioSpectrum® Imaging 
System.  
2.2.16.8 ssDNA Concentration and purification 
The generated ssDNA was purified using the Oligo Clean and Concentrator™ kit 
(Zymo Research, USA), according to the manufacturer’s instruction. The 
digested products were transferred into a clean 2 mL Eppendorf tube; to which 
twice the volume of the Oligo binding buffer was added. Absolute ethanol (400 
µL) was then added and the mixture was pipetted a few times then transferred 
into a Zymo-Spin™ Column that was suspended in a collection tube. The DNA 
solution was centrifuged at 10 000 rpm; (30 sec) and the flow-through was 
discarded. The DNA Wash Buffer (750 µL) was added to the column, followed 
by centrifugation as above. The flow-through was discarded and the column was 
transferred into a clean 1.5 mL Eppendorf tube. Nuclease-free water (35 µL) was 
added into the column and centrifuged to elute the DNA. The purified DNA was 
quantified using the DNA Qubit Assay and analysed by agarose gel 
electrophoresis. 
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2.2.16.9 Monitoring the evolution of the aptamers 
The SELEX process was repeated 14 times until the aptamers were highly 
enriched for their target. Before monitoring evolution, SELEX rounds were 
selected based on the stringencies introduced in different rounds (Table 2.10).  
The samples were PCR amplified using the optimum number of cycles (25 
cycles), the PCR products were analysed on a 3 % agarose gel and then viewed 
on UVP BioSpectrum® Imaging System.  
Table 2. 10: The criteria used for monitoring the evolution 
Recommended 
no. of SELEX 
rounds 
SELEX category Description of 
activities 
Selected rounds 
for monitoring 
the evolution 
1 – 4 Normal selection 
of aptamers 
 
30 min incubation 
of beads and 
target protein (30 
pMol) for both 
negative and 
positive SELEX 
Round 3 
5 – 7 Introduction of the 
selection 
stringency on 
aptamers (exclude 
counter SELEX) 
20 min of  
incubation of 
beads and target 
protein (15 pMol) 
for both negative 
and positive 
SELEX 
Round 7 
8 - 14 Stringency and 
counter SELEX 
introduction 
 
20 min of  
incubation of 
beads (negative 
SELEX) and 10 
min incubation of 
counter and target 
proteins (15 
pMol) for both 
counter and 
positive SELEX 
Round 11 and 14 
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2.2.16.10 Characterization of the selected aptamers  
2.2.16.10.1 Electrophoretic Mobility Shift Assay (EMSA) 
Binding of the aptamers to TAGLN2 was analyzed through a native gel 
electrophoresis mobility shift assay (EMSA). The aptamers were conditioned for 
binding by heating at 95 °C followed by 60 min incubation at 25 °C. The full 
length and variable aptamers (5 µM) were incubated in the presence of an 
increasing amount of protein target (ranging from 5 to 500 nM) for 30 min at 25 
°C (30 µL final volume). Control proteins and aptamers were introduced to 
increase aptamer selectivity to the target protein (TAGLN2). The proteins used as 
controls included HSA and 6X His peptide, while MUC1-aptamers were used as 
the control aptamers (Muthelo and Meyer, 2015). After incubation, 10 µL of the 
samples were loaded onto a 8 % non-denaturing polyacrylamide gel. The gel was 
run in TBE buffer (1 X) at 105 V for 1 hour. The gel was stained with 2.5 µg/mL 
Ethidium Bromide for 20 min. The gel was visualised in the UVP BioSpectrum® 
Imaging System and analysed with Vision Works™ LS Image Acquisition and 
Analysis Software. 
2.2.16.10.2 Surface Plasmon Resonance (SPR) 
SPR studies were conducted using the SPR ProteOn XPR36. The HTE chip was 
activated by nickel sulphate (10 mM) at a flow rate of 30 µL/min. The His-tagged 
TAGLN2 ligand was injected immediately to avoid nickel (II) ion leakage. The 
ligand was immobilized on the chip at a concentration range of 5 to 10 µg/mL, 30 
µL/min flow rate and association/dissociation time of 300 seconds in a final 
volume of 150 µL.   
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The ligands were stabilized with 1M NaCl. The analytes (FL and TR aptamers) 
were then injected into the chip at a flow rate of 25 uL/min flow rate at 300 
seconds association/dissociation constants. The analytes were injected at different 
concentrations ranging from 0.1 to 20 µM. Imidazole was introduced in one of 
the channels as a control. The experiment was repeated thrice. The results were 
analysed by the Bioevaluation software to assess binding between the TAGLN2 
and the aptamers.  
2.2.16.11 DNA Sequence analysis and in silico analysis of the generated 
aptamers 
2.2.16.11.1 Quantification of the evolving aptamers using Image J 
The intensity of the bands on the agarose gel was quantified by the ImageJ 
software (NIH, USA). The relative band intensity was plotted against the selected 
aptamer rounds during enrichment. The program was employed as described by 
the manufacturer’s manual (https://imagej.nih.gov/ij/download.html). A bar graph 
was constructed to distinguish the negative SELEX from the positive SELEX.  
2.2.16.11.2 Aptamers preparation and DNA sequence analysis  
The dsDNA samples generated from PCR scale-up were analyzed on agarose gel 
and then purified using the Oligo Clean and Concentrator™ kit (Zymo Research, 
USA), according to the manufacturer’s instruction. The DNA sample (10 ng/µL) 
was sent for sequence analysis by next generation sequencing (NGS) at Inqaba® 
biotech. 
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A basic service of sequencing reactions without repeat, and analysis of the DNA 
sequences (Bioanalyzer) upto 11 samples per DNA chip (IB MiSeqBioAna) was 
requested. The Miseq Library Prep was prepared according to Inqaba® biotech’s 
standard operating protocols using IB MiSeq Lib_DNA and MiSeq run. The 
resulting sequences were merged with Galaxy version 16.07 open web server 
(https://usegalaxy.org; Afgan et al., 2016) by Pair-End read merger. The data was 
analysed using Geneious 10.0.5 software (http://www.geneious.com; Kearse et 
al., 2012). 
2.2.16.11.3 Analysis of the aptamers by Geneious Software 
The DNA sequence analysis results obtained from Section 2.2.16.11.2 were sent 
as raw data, and they were imported into the Geneious software for analysis. The 
software was used to pair and merge the sequences amplified by the forward and 
reverse primers to form dsDNA. The sequences were used as the starting material 
for analysis.  The sequences that showed non-complementary forward and 
reverse sequences were discarded and considered to be the background noise. The 
complementary DNA strands (paired reads) were extracted based on the length of 
the library pool used during SELEX. The forward primer sequence was used as a 
reference when the merged sequences were blasted to identify aptamers with 
similar sequences. The sequences with the correct nucleotide sequences at the 5’ 
end were isolated from the sequences that lacked the correct nucleotide sequence 
at the 3’ end. Sequences that appeared as duplicates were selected for further 
analyses as they were enriched to the target during SELEX.  
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Top ten duplicates were aligned using the ClastalW Alignment, the sequences 
obtained from the TR and the FL aptamers were aligned to determine enriched 
aptamers. A phylogenetic tree was constructed for both the TR and the FL 
aptamers. The aptamer DNA sequences were then divided into clades based on 
their conserved sequences. The selected aptamers were subjected to MEME Suite 
to confirm the conserved motifs. 
2.2.16.11.4 Analysis of the motifs in the aptamers by MEME Suite Software 
The MEME Suite software was used to confirm the conserved motifs identified 
from Section 2.2.16.11.3. The selected aptamer sequences were imported into the 
MEME Suite software. Sequences that showed conserved motifs within the 
aptamer pool were compared to each other; their secondary structures were 
predicted by Mfold web server.   
2.2.16.11.5 Aptamers secondary structure prediction using the Mfold web 
server 
Secondary structure predictions of the candidate aptamer sequences were 
constructed using an online software tool, Mfold 
(http://unafold.rna.albany.edu/?q=mfold; Zuker, 2003). The parameters set for in 
silico analysis were as follows: temperature (25°C), Mg ions (1.5mM) and Na 
ions (0.138M).  
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CHAPTER 3 
RECOMBINANT EXPRESSION AND PURIFICATION OF 
POTENTIAL TB BIOMARKER PROTEINS IN E. COLI 
 
3.1 Introduction 
In silico approaches were used to identify potential TB biomarkers, the proteins 
were selected by profiling serum proteins that were shown through proteomics 
studies to be differentially expressed in TB patients. Human serum has proved to 
be a reliable source of biomarkers that are related to pathological and 
physiological processes of diseases (Marko-Varga et al., 2005) and the blood 
samples of TB patients are also used in several TB diagnostic tests.   
Proteins that are upregulated in the sera of TB patients can potentially be used as 
TB biomarkers (Achkar et al., 2015). Six serum proteins (IGFBP6, ISG15, 
S100A9, RBP4, GrA and TAGLN2) were shown to be upregulated in the sera of 
TB patients (Achkar et al., 2015; Guggino et al., 2015; Hare et al., 2015; Xu, et 
al., 2015). The first step towards using these potential biomarker proteins in 
diagnostics is the identification of molecules that can detect these proteins. 
Although antibodies can be used, these molecules have several limitations as 
discussed in Section 1.9.1. DNA aptamers are more suitable for applications in 
the recognition of proteins. The identification of DNA aptamers using the SELEX 
procedure requires large amounts of the purified biomarker protein. In this study 
recombinant DNA technology was used to clone genes encoding the potential 
biomarker proteins into protein expression vector (pET100/D-TOPO
®
). Large 
scale expression of the protein was then performed in E. coli.  
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3.2 Results and discussions 
3.2.1. Identification of TB biomarker proteins   
Six TB biomarker proteins were identified as potential TB biomarkers from 
literature using methods described in Section 2.2.1. These proteins are Insulin-
like Growth Factor Binding Protein 6 (IGFBP6), Interferon-stimulated Gene 15 
(ISG15), Calcium Binding Protein (S100A9), Retinol Binding Protein 4 (RBP4), 
Granzyme A (GrA) and Transgelin-2 (TAGLN2) (Table 3.1).  
     Table 3. 1: Potential biomarker proteins identified from literature 
TB Biomarkers Acronym Source 
Insulin-like growth factor binding protein 6  IGFBP6 Achkar et al., 2015 
Interferon- stimulated gene 15 ISG15 Hare et al., 2015 
Protein S 100A9  S100A9 Xu et al., 2015 
Retinol binding protein 4  RBP4 Xu et al., 2014 
Granzyme A  GrA Guggino et al., 2015 
Transgelin 2  TAGLN2 Achkar et al., 2015 
    
3.2.1.1. IGFBP6 gene 
IGFBP6 gene is preferentially expressed in the soft tissues in the presence of M. 
tb (Fagerberg et al., 2014; Kiso et al., 2017). It is also expressed in human 
cancerous cells such as the prostate cancer cell line (LNCaP). The gene encodes 
the serum potential TB biomarker IGFBP6 protein.   
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3.2.1.2. ISG15 gene 
The ISG15 gene is secreted by the interferon (IFN) due to presence of M. tb.  
The gene is preferentially expressed in the blood (Li et al., 2009) and can also be 
expressed in human cancerous cells including the human lung carcinoma (A549), 
cervical cancer (HeLa cells) and the human liver cancer (HepG2 cell line). The 
ISG15 gene encodes the potential TB biomarker ISG15 protein. 
3.2.1.3. S100A9 gene 
The S100A9 gene is preferentially expressed in the bone marrow (Li et al., 2009) 
and encodes the secretory potential TB biomarker S100A9 protein. The gene can 
also be expressed from human cancerous cervical lesions such as HeLa, CasKi 
and CaVO-3 cell lines.  
3.2.1.4. RBP4 gene 
The RBP4 gene is differentially expressed in the blood due to immunity. The 
immune system is stimulated in response to diabetes and cancer such as the one 
affecting the ovaries (ovarian cancer, SKOV-3 and SW626 cell lines) (Cheng et 
al., 2014). 
3.2.1.5. GrA gene 
GrA gene is preferentially expressed in the larynx (Guggino et al., 2015) where it 
encodes the cytosolic potential TB biomarker GrA protein.  
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3.2.1.6. TAGLN2 gene 
The TAGLN2 gene is expressed in several cancer cells such as prostate, breast, 
colon and lung cancers (Stanier et al., 1998).  
It encodes the serum TAGLN2 protein, recently identified as a potential 
biomarker to detect the presence of M. tb in both the latent and active TB 
infection (Achkar et al., 2015). The TAGLN2 protein can potentially also be used 
to detect TB not only at the early stages, but also progressive TB since it is also 
expressed in the TB individuals co-infected with HIV (Achkar et al., 2015).  
3.2.2 PCR amplification of genes encoding TB biomarker proteins 
Genes encoding these biomarker proteins were amplified from cDNA prepared 
from several human cell lines. This include skin fibroblast cell line (KMST-6) 
and cancer cell lines (CaoV-3, MCF-7and SKOV-3). RNA was isolated from 
these cells and the cDNA was synthesized as described in Sections 2.2.2 and 
2.2.3, respectively. Gene specific PCR primers were designed as described in 
Section 2.2.4. These primers were used to amplify the 6 genes. Table 3.2 shows 
the 6 genes (and their expected sizes) identified from literature. 
     Table 3. 2: Potential biomarker proteins identified from literature and their sizes 
TB Biomarkers Acronym Gene Size (bp) 
Insulin-like growth factor binding protein 6  IGFBP6 616 
Interferon- stimulated gene 15 ISG15 465 
Protein S 100A9  S100A9 360 
Retinol binding protein 4  RBP4 628 
Granzyme A  GrA 456 
Transgelin 2  TAGLN2 600 
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The integrity of RNA extracted from the cells (SKOV-3, KMST-6 and MCF-7) 
was evaluated by agarose gel electrophoresis (AGE) (Figure 3.1).  
The presence of both 28SrRNA and 18SrRNA subunits provides insights into the 
success of RNA extraction and its integrity before downstream applications 
(Jakovljevic et al., 2004; Tabb-Massey et al., 2003). As shown in Figure 3.1, the 
presence of 28S rRNA at ≃ twice the amount of 18S rRNA (as shown by the 
intensity of the bands) confirmed the quality and concentration of the extracted 
RNA. The rRNA is highly abundant, making up ≃ 95 % of the total RNA in all 
the mammalian cells (Fu and Gong, 2017). Majority of this is made up of the 28S 
and the 18S rRNA. Thus detection of these rRNA subunits can been used to 
confirm the presence of the intact RNA in a given sample (Fleige and Pfaffl, 
2006; Strand et al., 2007). From the Figure 3.1, the absence of smearing also 
indicated good quality RNA.  
 
Figure 3. 1: Agarose gel electrophoresis (AGE) analysis of the RNA integrity extracted from 
human cell cultures..The samples were extracted from human cancer (SKOV-3 and MCF-7 
cells) and non-cancer cells (KMST-6 cells). M: O’GeneRulerTM 100bp Plus DNA Ladder, 1: 
SKOV-3, 2: KMST-6 and 3: MCF-7 cells extracted RNAs. The presence of the two rRNA 
subunits (18sRNA and 28sRNA) is indicated on the gel image. 
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SKOV-3 and KMST-6 cells yielded a better quality and quantity of RNA (seen as 
intense bands in Figure 3.1) compared to MCF-7 cells (less bright bands).  
It was expected that the different cell lines might vary in their expression profile 
for these genes. It is for this reason that more than one cell line was used. The 
extracted RNA was used to synthesise complementary DNA (cDNA) (as 
described in Section 2.2.3).  
3.2.3 cDNA Synthesis 
cDNA was synthesized using the Transcriptor First Strand cDNA Synthesis Kit 
(Roche Diagnostics) as described in Section 2.2.3. The protector RNase inhibitor 
supplied in the kit protected the degradation of the RNA by RNases while the 
reverse transcriptase (RT) was used to translate the RNA to cDNA. Like 
polymerase, reverse transcriptase needs a primer (Random Hexamer Primer) to 
start the DNA synthesis and this created one DNA (cDNA) strand 
complementary to the RNA strand in a DNA-RNA hybrid. The Reverse 
Transcriptase has RNase H activity that degrades the RNA strand in RNA: DNA 
hybrids, leaving single stranded cDNA ready for PCR. In this case, total RNA of 
which mRNA makes up 1-5% was used as a template for cDNA synthesis. 
 Genes encoding the selected TB biomarker proteins were amplified from the 
cDNA obtained from various mammalian cells as shown in Table 3.3, using 
conventional PCR. The amplicons were analysed by AGE. As shown in Table 
3.2, the genes vary in size. The expected size of each gene was correlated with 
their sizes on the gel (Figure 3.2 A-D). Figures 3.2 A and B showed amplification 
of the 4 genes (ISG15, IGFBP6, S100A9 and GrA) from cDNA generated from 
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MCF-7 and SKOV-3, while the other two genes (RBP4 and TAGLN2) were 
amplified from KMST-6 and CaOV-3 derived cDNA (Figures 3.2 C and D). 
Table 3. 3: Potential TB biomarkers and their source cell lines for PCR  
Gene  Cell line 
IGFBP6 Prostate cancer (LNCaP) cell line 
ISG15 Cervical cancer (HeLa cells) 
Human liver cancer (HepG2 cell line) 
S100A9 Cervical lesions (CaVO-3 cell lines) 
RBP4 Ovarian cells (SKOV-3) 
GrA Cervical lesions (CaVO-3 cell lines) 
TAGLN2 Cervical lesions (CaVO-3 cell lines) 
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Figure 3. 2: PCR amplification of the genes encoding the selected TB biomarker proteins from cDNA derived from human cell lines. Gel images A, B, 
C and D represents genes amplified from MCF 7, SKOV-3, KMST-6 and CaOV-3 cells, respectively. M: 1kbO’gene ruler, -: negative control, Lanes 1-11 
where, PCR results for 1: ISG15 (465bps); 2: IGFBP6 (616bps); 3: S100A9 (360bps), 4: GrA (456bps); 5: TOPO positive control (750bps); 6: ISG15 (465 bps); 
7: IGFBP6 (616bps); 8: S100A9 (360bps); 9: GrA (456bps); 10: RBP4 (628bps) and 11: TAGLN2 (600bps).  
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The amplified gene products (PCR amplicons) were purified using a commercial 
kit (Section 2.2.6) and quantified using the Qubit (Section 2.2.7). The samples 
were then stored at -20
0
C until further analysis.  
3.2.4 Cloning of the genes encoding the TB biomarker proteins 
The six genes were cloned into the pET vector using the Champion
TM
 pET 100 
Directional TOPO
®
 Expression Kit. The kit uses a five minute cloning strategy to 
directionally clone blunt-ended PCR products into the vector as shown in Figure 
3.3 (Cheng and Shuman, 2000). The vector contains topoisomerase I (of the 
Vaccinia virus origin) which is responsible for the insertion of the blunt-ended 
PCR product (Figure 3.3). During cloning, the enzyme cleaves the phosphate 
group connecting two nucleotide bases in the opposite strands at the 3′ and the 5′ 
carboxyl groups. The cleavage occurs in the 5′-strand after the CCCTT sequence 
(Shuman, 1994), the GTGG overhang sequence in the vector initiates cloning by 
displacing the GTGG sequence in the 5’ strand of the blunt-ended PCR products.  
The CACC sequence in the 3′ strand then anneal to the complementary GTGG 
overhang sequences in the vector (Figure 3.3) (Cheng and Shuman, 2000).  
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Figure 3. 3: Principle of the directional TOPO
®
 cloning strategy (Invitrogen, 2017).  
 
The amplified genes encoding the selected TB biomarker proteins were cloned 
into the pET vector in a 2:1 molar ratio of the PCR product: pET
®
 vector (section 
2.2.8). Randomly selected colonies were screened for the presence of the genes of 
interest. Colony PCR screening was performed using the gene-specific primers. 
Ten colonies per plate were selected for screening. The colonies were diluted 
1:10 in distilled water and used as templates in the colony PCR (as described in 
Section 2.2.9). Figure 3.4 shows one of these ten colony PCRs for each of the 6 
of the TB biomarker genes. The PCR amplicons for 3 of the genes (S100A9, GrA 
and TAGLN2) were the expected size (360bps, 456bps and 600bps, respectively). 
The clones were therefore considered positive for successful cloning.   
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ISG15 (465 bps) showed non-specific PCR amplification as evidenced by the 
presence of multiple bands, while the IGFBP6 (616 bp) PCR amplified a product 
that was less than the expected size, the amplicon was at ±100 bp. The positive 
control was provided in the kit to determine the PCR efficiency. Glycerol stocks 
were prepared for the positive colonies, TAGLN2, GrA and S100A9, (as described 
in Section 2.2.10) and stored at -80 
0
C until ready for downstream applications. 
 
Figure 3. 4: Colony PCR screening for the genes encoding the potential TB biomarker 
proteins using gene-specific primers. M: 1kb O’gene ruler, +: positive control (TOPO DNA, 
750 bps), 1: ISG15 (465bps), 2: IGFBP6 (616bps), 3: S100A9 (360bps), 4: GrA (456bps) and 5: 
TAGLN2 (600bps) genes. The circles represent genes S100A9 and GrA respectively. 
 
Based on Figure 3.4, only 3 of the 6 genes were successfully cloned. Because of 
this low success rate, it was decided to also confirm the presence or absence of 
genes by performing a PCR on the plasmid DNA that was produced from the 
clones. DNA minipreps were prepared for all the clones that were screened by 
colony PCR. The plasmid DNA samples were quantified using the Qubit. Using 
T7 primers, conventional PCR was used to amplify inserts present in the plasmid 
DNA (Figure 3.5).   
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Figure 3. 5: PCR screening for the genes encoding the potential TB biomarker proteins 
from plasmid DNA using T7 primers. M: 1kb O’gene ruler, -: negative control, 1: ISG15 
(465bps), 2: IGFBP6 (616bps), 3: S100A9 (360bps), 4: RBP4 (628bps), 5: GrA (456bps) and 6: 
TAGLN2 (600bps). The arrows are pointing to the expected sizes of S100A9, GrA and TAGLN2.  
 
From Figure 3.5, the clones for only two of the genes (S100A9 and TAGLN2) 
were positive and produced amplicons at the expected sizes. There was no 
amplification for the ISG15 gene. The sizes of the amplicon obtained from 
IGFBP6, RBP4 and GrA were not corresponding to the expected sizes and were 
therefore considered as negative. The PCR for GrA produced an amplicon that 
was similar in size to TAGLN. It is possible that the GrA PCR reaction was 
contaminated with TAGLN. These results suggest that colonies for only TAGLN2 
and possibly also S100A9 were successfully cloned into the pET TOPO vector. 
The other genes produced false positive colonies during antibiotic selection this 
might be attributed to the recircularization of the vector during cloning. The 
vector can close up due to the possibility of a reverse reaction between the 
hydroxyl group in the 5′ end of the cleaved strand and phosphate group in the 3′ 
end of the complementary strand (Shuman, 1994). This consequently resulted in 
closing up of the vector by itself and producing false positive colonies without 
the inserts.  
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To validate the successful cloning and the orientation of the TAGLN2 gene in the 
vector system, this clone was sent to Inqaba Biotech
TM
 for DNA sequence 
analysis. 
3.2.5 DNA Sequence analysis of TAGLN2 and S100A9 clones  
Agar plates containing ampicillin resistant colonies of TAGLN and S100A9 were 
sent to Inqaba Biotech
TM
 for DNA sequence analysis using the universal T7 
primers, to confirm the presence of the TAGLN gene and to determine the 
orientation of the gene insert. The DNA sequence of the vector (including the 
cloning site and the sites where the T7 primer anneals) is shown in Figure 3.6. 
Using T7 primers will result in amplification of some part of the vector sequences 
from position 208 to 455. 
 
 
Figure 3. 6: TOPO 10 vector DNA sequences for the multiple cloning site from positions 
121-480 (Invitrogen, 2017). Cloning of genes start from CACC sequence (shown in blue) at 
position ≃390 bp.   
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After DNA sequence analysis, the sequence data was blasted in Addgene 
(https://www.addgene.org/analyze-sequence/), to confirm the presence of the 
inserts (gene of interests) within the plasmid DNA. Only TAGLN2 gene sequence 
was correct and is shown in Figure 3.7. The TAGLN2 gene sequence was in the 
correct orientation, as confirmed by the presence of the CACC sequence added at 
the 5′ end of the forward primer, to allow complementary base pairing with the 
GTGG overhang at the 3’ end of the vector. There were no mutations observed in 
the TAGLN2 DNA sequence.  
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Figure 3. 7: DNA sequence generated for the TAGLN2 clone using the universal T7 primers. The DNA sequence in black shows the insert, starting with 
the CACC sequence (in bold and underlined) which is part of the forward PCR primer and the stop codon TTA (in bold and underlined). The DNA sequence in 
orange shows the ends of the pET vector.  
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The TAGLN2 gene sequences were further validated by BLAST analysis using 
the NCBI online tools. A translated BLAST against the Homo sapiens gene 
database produced Homo sapiens TAGLN2 gene (Accession number: 
NM_001277224.1) as the gene inserted into the pET vector (Figure 3.8). The 
insert in the pET clone matched the TAGLN2 protein sequence with a 100% 
identity. This confirmed that the TAGLN2 gene was successfully cloned into the 
pET vector into the correct orientation. 
 
Figure 3. 8: BLAST analysis of the DNA sequence generated for the TAGLN2 clone. A 
shows a map of the alignments and their identities of the top 25 sequences in the database that is 
similar to the DNA sequence of the TAGLN2 clone. B shows the translated amino acid sequence 
for the sequence with the best match to the TAGLN2 clone.  
 
Cloning of S100A9 was not successful since the DNA sequence generated for this 
clone did not match the protein sequence of S100A9. It is possible that this clone 
too was generated as a false positive colony during antibiotic selection, which 
may be attributed to the recircularization of the vector during cloning. 
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3.2.6 Expression and purification of TAGLN2 recombinant protein 
3.2.6.1 Screening of TAGLN2 expression in E. coli cells  
Expression of TAGLN2 protein was screened in two bacterial strains, the BL21 
CodonPlus
TM
 and the BL21 Star
TM 
(DE3) E. coli cells. The TAGLN2-TOPO 
construct was transformed into the BL21 cells as described in Section 2.2.12 
where 5 colonies were picked from each strain for expression screening.   
Pilot protein expression was induced by addition of 1mM IPTG in 5 mL bacterial 
cultures, and then allowed to grow for ~16 hrs. Bacterial systems provide the 
merits of simplicity, speed, low costs and recombinant protein expressions in 
large biomass (Carstens et al., 2001). Protein expression in the two bacterial 
strains, the BL21 CodonPlus
TM
 and BL21Star
TM
 was analysed by SDS-PAGE, 
not much differences between the uninduced and induced samples was observed 
in the gels (data not shown).  To further investigate protein expression, the 
samples were purified using nickel-bead affinity chromatography. The purified 
proteins were used to screen for protein expression as well as protein solubility. 
Figure 3.9 represent the expression and affinity purification profile of TAGLN2 
protein from the two different bacterial strains, the BL21 CodonPlus
TM
 (Figure 
3.9 A) and the BL21Star
TM
 (Figure 3.9 B). The HIS–tagged TAGLN2 protein 
was successful expressed and purified in the two bacterial strains as indicated by 
a single protein band (E1-2, Figure 3.9 A and B); the purified protein had a size 
equivalent to TAGLN2 molecular weight of ≃24 kDa in both strains.  
 
http://etd.uwc.ac.za/
80 
 
 
Figure 3. 9: Large scale expression of the HIS-tagged TAGLN2 protein and purification by affinity chromatography. The protein was expressed in 
BL21 CodonPlus
TM
 (A) and BL21 Star
TM 
(DE3) (B) E. coli cells. M: 250 kDa Unstained Broad Range Protein Ladder; P: pellet; L: lysate or supernatant 
fraction; F: flow through; W1: first wash with 5mM imidazole; W2: second wash with 20mM imidazole; E1-3:  elution fraction with 400 mM imidazole; and 
NaCl2: elution of protein with 400 mM imidazole and 1M NaCl2.  
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The BL21 Star
TM 
E. coli strain was recommended by the TOPO cloning kit 
supplier, and expected to have higher activity than the BL21CodonPlus
TM
 strain. 
However, the opposite was true as the latter showed higher protein quantities than 
the BL21 Star
TM
. The BL21 Star
TM 
was recommended because it contains both 
the lacUV5 promoter and the λ DE3 lysogen which is capable of enhancing the 
expression of the desired proteins through T7 RNA polymerase. The polymerase 
is coded by genes in the λ DE3 lysogen and also lacks two of the key protease 
activities including the Lon protease and a mutation in the outer membrane 
OmpT protease. The lack of these two key proteases reduces degradation of 
heterologous proteins expressed in the strain. In addition, these strains also had 
mutated rne 131 gene that is encoded by RNase E which in turn improves the 
yield of the desired protein (Invitrogen, 2006). 
The solubility of the protein was also assessed; there was no indication of 
overexpression in the pellet fraction (Figure 3.9, P). The recombinant protein was 
present in the supernatant, and proves to be soluble. If the protein was present in 
the pellet fraction, then the protein would have been considered insoluble and a 
membranous protein and not a cytosolic protein (Thoring et al., 2016). The 
recombinant protein (HIS-TAGLN2) seemed to be stable as there was no 
degradation (multiple bands) from both gels. The protein was then dialysed for 16 
hours and then quantified by the Qubit
TM
. The concentration from small scale 
sample was 550 ng/μL. The sample was then stored at -20 0C until ready for 
downstream applications. Due to the increase in the yield of TAGLN2 protein 
from Figure 3.9A compared to Figure 3.9B, the CodonPlus
TM 
strain was selected 
for the scale-up protein expression. 
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3.2.6.2 Large-scale expression of TAGLN2 protein 
TAGLN2 recombinant protein expression was up-scaled to 2L using the BL21 
CodonPlus
TM
 strain. The enhanced protein expression in CodonPlus E. coli cells 
have been associated with the presence of extra copies of tRNA genes that are rare 
in other E. coli strains (Carstens et al., 2001), the tRNA genes promote protein 
expression that would otherwise be prevented. The CodonPlus
TM
 strains also 
have protease deficiency as they lack both the Lon and OmpT (as mentioned in 
Section 3.2.6.1). The deficiencies in these proteases help to preserve the integrity 
of the recombinant proteins. Advantages the CodonPlus
TM
 strain has over Star
TM
 
are Hte modifications that are responsible for elevating the transformation 
efficiency. In addition, they also lack endA1, which prevent degradation of the 
plasmid DNA during transformation. These factors may help to maintain the 
integrity of the mRNA, stabilizing it and improve the yield of the translated 
protein (Carstens et al., 2001).  
The soluble protein fraction (supernatant) was purified as before and analysed by 
SDS-PAGE. As shown in Figure 3.10, the recombinant protein (HIS-tagged 
TAGLN2) from large-scale expression was eluted with 400 mM imidazole 
buffer. Two protein bands were observed (Figure 3.10, E1) at 24 kDa. This 
probably might have been due to protein degradation attributed to poor storage 
conditions of the samples. The samples were stored at 4 
o
C after purification. 
Thus, it is important to store the samples at -80 
0
C prior to their downstream 
applications. 
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Figure 3. 10: Affinity purification of HIS-tagged TAGLN2 recombinant protein expressed in 
BL21 CodonPlus
TM
. M: 250 kDa Unstained Broad Range Protein Ladder; S: supernatant 
fraction; F: flow through; W1-2: first wash with 5mM imidazole; W3:  washed with 20mM 
imidazole; E1-2: fraction of the eluted protein with 400 mM imidazole; E3: small-scale purified 
protein (control).  
  
The purified protein sample was quantified by the Qubit
TM
, the concentration was 
360 ng/μL. Surprisingly, this concentration was lower than the concentration 
obtained during pilot expression (550 ng/μL, Section 3.2.6.1). Most of the protein 
washed off as the flow through (F) and wash 1 (W1) samples, an indication that 
the concentration of Ni-beads was not enough to bind all the protein (i.e. the 
beads were over-loaded). The purified sample was concentrated in a 10 kDa 
concentrator, since the protein of interest (HIS-tagged TAGLN2) has a higher 
molecular weight (24 kDa) and would not pass through the pores of the 
membrane, resulting in the concentration of the protein. The protein was dialysed 
in PBS overnight at 4 °C and subsequently freeze-dried.  The dry weight of the 
lyophilized protein was 69 mg. The lyophilized HIS-TAGLN2 protein was then 
stored at 4
 0
C for future use.  
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3.3 Conclusion 
Computational tools were used to identify 6 potential serum biomarker proteins 
for TB diagnosis. The identification of DNA aptamers against these proteins 
required large quantities of these proteins. This required the cloning of the genes 
encoding these proteins and their recombinant expression in E. coli. Although all 
6 genes were successfully amplified by PCR from human cell cultures, only one 
of these genes, TAGLN2 was successfully cloned into the protein expression 
vector, pET100/D-TOPO
®
. This was confirmed by DNA sequence analysis. 
Through large expression of TAGLN2, a significant amount of this protein was 
purified from E. coli that was transformed with the pET100/D-TOPO
® 
vector. 
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CHAPTER 4 
THE SELECTION OF APTAMERS AGAINST TAGLN2 AND 
SEQUENCE ANALYSIS BY BIOINFORMATICS 
4.1 Introduction 
Systematic Evolution of Ligands by EXponential enrichment (SELEX) is an in 
vitro process that is used to produce DNA aptamers that are highly enriched for a 
specific target molecule (e.g. small molecules, proteins, nucleic acids, viruses, 
bacteria, whole cells and tissues). These aptamers bind to these target molecules 
with high affinity and specificity. These features of aptamers can be exploited in 
the development of diagnostic systems, which require molecules that can 
recognize protein biomarker targets with high specificity. The SELEX process is 
divided into several steps that are repeated several times (8 - 25 rounds). The 
affinity and specificity of the aptamers for the target generally increases with 
increasing rounds of selection. Dissociation constants (Kd) in the nanomolar 
ranges can be attained. The steps are as follows: incubation of the random DNA 
aptamer library with the target molecule which is immobilized in a matrix, 
separation of the pools of bound and unbound aptamers, amplification of bound 
aptamers through PCR, the generation of single-strand DNA nucleotides that will 
serve as a template for the next round of selection, elution of bound aptamers 
from their matrix, followed by aptamer purification and lastly the determination 
of the aptamer sequence (Tsao et al., 2017).  
In this study nickel - nitrilotriacetic acid (Ni-NTA) magnetic beads were used as 
the matrix to immobilize a potential TB biomarker protein, TAGLN2. The NTA-
moiety is covalently attached to the particle surface and facilitates the binding of 
a polyhistidine-tag.  
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This method separates bound and unbound aptamers by using a magnet to capture 
aptamer/protein-complexes on magnetic beads. Binding of the aptamer/protein-
complex to the magnetic bead is facilitated by a fusion tag on the protein of 
interest.  In this study a commercial TAGLN2 protein (Abcam Biotech
TM
) with a 
polyhistidine-tag was used as the target for SELEX since the recombinant 
TAGLN2 protein produced and discussed in Chapter 3 was not available at the 
time SELEX was performed. 
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4.2 Results and Discussion 
As indicated above SELEX is a repetitive selection process, which involves 
incubation, separation and PCR amplification. Section 4.2.1 will describe and 
discuss the results obtained for one SELEX round in detail, while the full data set 
for the selection of aptamers against TAGLN2 will be discussed in Section 4.2.2. 
4.2.1 Processes involved in the selection of aptamers  
A DNA aptamer library with short fragments (97 bp) and short random regions 
(≃53 nucleotides) were used in this study as such libraries were demonstrated to 
be sufficient for selection of aptamers against several target molecules 
(Svobodova et al., 2013). Bock and colleagues (1992) showed that a 96 bp DNA 
aptamer library was able to target a human thrombin protein (Bock et al., 1992). 
Also, Legiewicz and co-workers (2005) demonstrated that interference in the 
aptamer selection process could occur when longer (90 nucleotides) and shorter 
(16 nucleotides) randomized regions are employed to recognize the same target 
(Legiewicz et al., 2005). Randomized regions of ≃30-60 nucleotides are 
considered the ideal length. DNA aptamers were preferred for this study since 
DNA is more stable than RNA molecules. Due to the presence of a 2’OH group, 
RNA molecules are more unstable and prone to hydrolysis when exposed to a 
higher temperatures and an environment with a basic pH (James, 2000; Kusser, 
2000).  
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4.2.1.1. Determining the optimal number of PCR cycles by pilot PCR 
A random single stranded DNA library was incubated with the target protein 
(histidine-tagged TAGLN2) at a fixed concentration (300 pM ssDNA and 30 
pM TAGLN2 protein) for 30 min as described in Section 2.2.16.3.  
The DNA aptamer library comprised of millions of random oligonucleotide 
sequences each with a length of ≃97 bp. Each oligonucleotide (full length/ 
FL) sequences consisted of a random (variable) region of ~53 bp flanked by 
a ~21 to 23 bp primer sequences at the 5′ and 3′ ends of the aptamer. 
Following the separation of the bound and the unbound aptamers, the next 
step of SELEX requires the PCR amplification of the bound aptamer 
sequences. Mutations are often introduced during PCR amplification and can 
result in non-specific PCR products, which can reduce the success of the 
downstream applications of the aptamer (Lorenz, 2012). Several methods 
have been used to step-wise monitor the evolution of the DNA pools after 
each round of SELEX (Qu et al., 2016; Takahashi et al., 2016). These 
include the use of the nuclear magnetic resonance (NMR) which is efficient 
in the analysis of the structures of RNA molecules (Amano et al., 2017). The 
use of Surface Plasmon Resonance (SPR) and Electrophoretic Mobility Shift 
Assays (EMSA) have also been employed to assess the affinity of the DNA 
pools to the target molecule (Qu et al., 2016). However, SPR requires sensor 
chips onto which the target molecules or aptamers are immobilized. EMSA 
experiment requires that the aptamer pools or target molecules must be 
labelled with tags such as radioisotopes or fluorophores. Immobilization of 
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the reagents to the sensor chips and the use of fluorophores are time-
consuming and expensive. Aside from being expensive, all these methods 
might alter the structure and the binding properties of the target molecule to 
the aptamer library. Pilot PCR, which involves monitoring of the PCR 
amplicons by simply subjecting the PCR product to AGE and visualising the 
quality of the PCR product, is more cost effective. Pilot PCR was used in 
this study to determine the optimal number of PCR cycles that does not 
result in non-specific amplification or PCR artefacts. Pilot PCR was used to 
follow the progression of the PCR by analysing the PCR products 
periodically over the 25 cycles. Following the separation of the bound and 
the unbound aptamers, the aptamer-TAGLN2 conjugate was used a template 
in a pilot PCR.  
Figure 4.1 shows that using more than 15 PCR cycles results in non-specific 
amplifications as indicated by multiple bands present in lanes C20 and C25, 
representing 20 and 25 PCR cycles, respectively. Figure 4.1 shows that a 
single PCR product is produced at 10 PCR cycles, but that the yield is low. 
As the number of PCR cycles are increased from 10 the amount of non-
specific products are also increased.  
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Figure 4. 1: Pilot PCR to determine the optimum number of cycles that can generate more 
specific PCR products in SELEX. M: 10 bp marker, - : negative control while C5 to C25 are the 
number of PCR cycles.  
4.2.1.2. Large-scale PCR amplification of aptamers using the optimized PCR 
conditions 
Twelve cycles were chosen as the optimal number of PCR cycles based on the 
pilot PCR in Figure 4.1. Twelve cycles were used to PCR amplify the aptamers 
using the aptamer/TAGLN2 complex as template. These products were analysed 
by AGE. Figure 4.2 shows single amplicons at the expected size, ≃100 bp (97 
bps). Replicates of this reaction were performed to increase the amount of PCR 
product for the next step of SELEX. 
 
Figure 4. 2: Large scale amplification of aptamers using the optimum PCR cycles.. M: 10bp 
O’gene ruler, –: negative control, C12: PCR cycles. 
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4.2.1.3. Generation of ssDNA by asymmetry PCR  
PCR amplification during SELEX produces dsDNA, however ssDNA are 
required for binding to the target protein. Several methods have been employed to 
produce ssDNA from the PCR amplified dsDNA. The use of phosphorothioate 
modified forward or reverse primer in the PCR allows for the degradation of the 
unmodified strand in the dsDNA using an exonuclease enzyme.  
This can also be achieved by using a biotinylated strand that will bind to the 
streptavidin-activated membrane, separating the two strands of dsDNA. The use 
of a radioactive labelling of the sense strand works on the same principle as 
biotin-streptavidin separation. Asymmetry PCR (A-PCR) can also be used to 
generate ssDNA aptamers. In A-PCR unequimolar ratios between the forward 
and the reverse primers is used to produce both ssDNA and dsDNA (He et al., 
2013). These methods however have some limitations, for instance, A-PCR 
requires thorough optimization of factors such as primer ratios, annealing 
temperatures and number of PCR cycles for each individual library (He et al., 
2013). Changing parameters used in normal (symmetric or pilot PCR) PCR will 
also reduce PCR reaction efficiency (Pierce et al., 2005).  
Asymmetry PCR (A-PCR) was used to generate ssDNA aptamers. This was 
achieved by using unequimolar ratios between the forward and the reverse 
primers. To protect the sense strand from nuclease degradation the forward 
primer was also modified by adding phosphorothioate to the 5’ end. During A-
PCR, both ssDNA and dsDNA are produced and since the interest is in ssDNA, 
nucleases are used to digest DNA strands that are not protected by 
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phosphorothioate. A-PCR result in low PCR reaction efficiency (60 - 70 %) as a 
consequence of unequal primer concentrations, (Sanchez et al., 2004). A-PCR 
will promote amplification of the 5’ strand and generate mainly the ssDNA 
(Sanchez et al., 2004).  
PCR products from symmetry pilot PCR were used as template for A-PCR, a 5:1 
ratio of forward to reverse primer was used to generate ssDNA. The PCR 
products were analysed by AGE.  
Figure 4.3 shows dsDNA and the ssDNA products generated by A-PCR, the 
majority of the products were ssDNA based on the band intensities on the gel 
image. The dsDNA had a higher molecular weight than the ssDNA, as such 
ssDNA migrates faster than the dsDNA on the gel. The dsDNA products are 
likely to interfere with the binding affinity of the aptamers to their target during 
the selection process and they were removed by nuclease digestion.  
 
Figure 4. 3: Generation of ssDNA aptamers by assymetry PCR. M: 10bp O’gene ruler, –: 
negative control, C12: PCR cycles. 
 
The fact that the random DNA library used was 97 bp long, chances of aptamer 
diversity for the target pool was reduced and the efficiency of the selection 
http://etd.uwc.ac.za/
93 
 
process was thus improved. A-PCR was used in the first two rounds of selection. 
This is expected to increase the yield of the ssDNA and to decrease chances of 
forming non-specific products (He et al., 2013). The scale-up PCR was followed 
by a nuclease digestion step to remove the dsDNA.  
In this study, the A-PCR product was subjected to the T7 gene 6 exonuclease 
digestion to remove dsDNA. The exonuclease digested samples was analysed by 
AGE, as shown in Figure 4.4A. The dsDNA observed in the A-PCR samples 
disappeared from the digested samples (T7). The resulting ssDNA was then 
purified (Figure 4.4 B) and resuspended in SELEX buffer in preparation for the 
next round of SELEX. 
 
Figure 4. 4: Production of ssDNA by A-PCR following digestion (A) and purification of the 
ssDNA (B). M: 100 bp O’gene ruler, A-PCR: Asymmetry PCR sample used as the control, T7: 
the digested amplicons generated from A-PCR, -ve: the negative control and Pur: purified 
product. 
 
4.2.2. Selection of aptamers against TAGLN2 protein 
In this study 14 rounds of SELEX was performed to obtain DNA aptamers that 
are specific for histidine-tagged TAGLN2 protein. Figure 4.5 shows the results of 
the pilot PCRs for each of these SELEX rounds. PCR amplification was 
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monitored at cycle (C) number 5, 10, 15 20 and 25. From figure 4.5, cycle 
numbers C10 from round 1 was selected for the large-scale PCR amplification 
while C15, C15, C15, C10, C15, C10, C15, C15, C15, C15, C20 and C15 were 
used for their large-scale PCR amplification from round 2 to 14 respectively.  
There is a high probability that some of DNA aptamers in the library may have a 
higher affinity for the magnetic beads than the protein target (TAGLN2), 
resulting in the false positive selection of aptamers that bind to the beads and not 
TAGLN2.  
To minimize this, a negative SELEX round (i.e. the incubation of the aptamer 
pool with the beads only) was introduced from SELEX round 2 (R2) to remove 
the aptamers that bind to the beads and not the TAGLN2 protein target. This 
means that all SELEX rounds from R2 were first performed using the magnetic 
beads as the target, followed by a positive SELEX (i.e. the incubation of the 
aptamer pool with the TAGLN2/bead complex). Aptamers that bound to the 
magnetic beads were removed and the supernatant containing unbound aptamers 
(which presumably do not bind to the beads) were used as the template for the 
positive SELEX.  
To monitor the evolution and enrichment of the aptamers produced during 
SELEX process, pilot PCRs were performed on both negative (indicated by – 
sign and the PCR cycle number) and positive (indicated by + sign and the PCR 
cycle number) SELEX samples (Figure 4.5). No clear difference in the profile of 
the PCR amplicons for the positive and negative SELEX can be observed in 
SELEX round 2 (R2). However from SELEX round 3 (R3) to 9 (R9) a significant 
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difference in the profiles of positive and negative SELEX can be observed. 
Figure 4.5 shows that pilot PCRs on negative SELEX samples yielded more 
intense bands and in some instances the PCR product also presented as a smear. 
This suggests that some aptamer sequences were successfully removed from the 
aptamer pool during negative SELEX.  
It is also clear that the cycle numbers of around 15 produce the best result since a 
single PCR amplicon is produced in most SELEX rounds. Cycle numbers higher 
than 15 produce smearing and multiple PCR bands. 
To further increase the selectivity and specificity of the aptamers for the target of 
interest, TAGLN2 counter SELEX was introduced from SELEX round 8 to 14. 
This was done by introducing an unrelated human protein, human serum albumin 
(HSA) into the SELEX procedure. From SELEX round 8 to 14 histidine-tagged 
TAGLN2 was replaced by recombinant histidine-tagged HSA as the target 
protein. Aptamers that bound to the HSA/bead complex were removed and the 
supernatant containing unbound aptamers were used as template for PCR 
amplification and the target for the next SELEX round. Counter SELEX can 
further assist the selection of aptamers that are specific for TAGLN2, since this 
will remove aptamers that can potentially bind to HSA, which is highly abundant 
in human serum. Since the aptamer that will be identified in this study will be 
used to detect TAGLN2 in serum samples, counter SELEX with HSA will also 
ensure that there is no undesirable binding of this aptamer to HSA, which is not a 
biomarker for TB, but is highly expressed in serum. This will limit false positive 
results in the diagnostic from serum samples. Based on the PCR profiles for 
SELEX rounds 8 to 14, there was no difference between positive and negative 
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SELEX (Figure 4.5). This showed that the selection was enriched and the quality 
of the PCR amplicon in R13, cycle number 20 was selected for the large-scale 
PCR amplification of aptamers before stopping at R14. 
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Figure 4. 5: Analysis of TAGLN2 aptamer evolution and enrichment during SELEX using pilot PCR. R1 – R14 indicate the SELEX round, while C5 – 
C25 indicate the PCR cycle number. Negative SELEX (indicated by the – sign) were introduced from R2 to R14. Counter SELEX was introduced from R8 to 
R14. M: 100 bp O’gene ruler, -:  negative control , C5 - C25: PCR cycle number. 
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It is generally expected that as the number of SELEX rounds increase, the number of 
aptamer variants in the selected or bound pool of aptamers should decrease and become 
more specific. This is expected result in an increase in the concentration of the PCR 
product. To verify this, pilot PCR amplicons in cycle number 15 (C15) in SELEX 
rounds 6, 10 and 13 was analysed by AGE and the PCR products were quantified by 
densitometry (Figure 4.6). Figure 4.6B shows that the yield of PCR product in negative 
SELEX rounds was much lower than the yield in the positive SELEX rounds for R6, 
R10 and R13. It is also clear that the yield of product increase with increasing PCR 
cycles. This suggests that the aptamer pool is becoming selective towards the target 
protein. 
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Figure 4. 6:  Monitoring of the evolution of TAGLN2 aptamers in R10 and R13. PCR yields were quantified by AGE (A) and densitometry analysis of the 
PCR bands (B). M: 100 bp O’gene ruler, C: negative control, the SELEX round (R) number with either – or + represent positive and negative SELEX. 
Densitometry analysis was done using ImageJ software.  
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4.2.3 Analysis of aptamers using bioinformatics tools 
The aptamers generated from the final round (Section 4.2.2) were prepared by 
PCR and the integrity confirmed by gel electrophoresis before being sent for 
sequence analysis. The resulting aptamer sequences were analysed by 
Bioinformatics (in silico) tools.  
In silico tools Geneious, MEME Suite software and the Mfold Web Server were 
used to analyse the DNA sequences which represented the isolated aptamers. The 
raw data containing the DNA sequences were uploaded in the Geneious interface 
where they were filtered until conserved sequence motifs were produced. The 
motifs were then subjected and confirmed by the MEME Suite.  
The selected aptamers were analysed by the Mfold Web browser to predict their 
secondary structures before synthesis. The aptamer structures provided insight 
into their binding patterns to the targets. These aptamers were then selected based 
on their binding capability to the target. 
4.2.3.1 Sample preparation and sequence analysis by Geneious   
The PCR products from SELEX R13, PCR cycle 15 (C15) was submitted to 
Inqaba® Biotech for DNA sequence analysis to identify the sequence of 
potential TAGLN2 aptamers. Direct ultra-high-throughput deep DNA 
sequencing was performed on the sample.  
Around 83,750 sequences were generated, which were further analysed using 
Geneious software (https://www.geneious.com/).  
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The aim was to verify that these sequences resembled the DNA aptamer library 
(i.e. that the sequences contained the variable region which was flanked by the 
conserved primer regions on the 5’ and 3’ ends) and to determine if there were 
similarities between any of the aptamer sequences. Following analysis using 
Geneious software, the 83,750 sequences were reduced to about 30, 000 unique 
sequences. Several sequences appeared multiple times and only the sequences 
that mapped to the forward primer used during selection was selected. This is not 
unexpected since it is anticipated that the relative concentrations of the aptamers 
will differ depending on their affinity for the target and due to the introduction of 
mutations by PCR. Figure 4.7 shows a pairwise sequence alignment (generated 
using ClustalW) of a list of ten full-length (FL, i.e. including the conserved 5’ 
and 3’ primer sequences) aptamer sequences that were most frequently replicated 
amongst the 83,750 sequences. The sequences were named Apt_1 to Apt_10. The 
conserved primer regions on the 5’ and 3’ ends, as well as the variable region 
(VR) were appeared in all these sequences. The frequency of repetition of the 
same sequence differed between the sequences. Apt_1, for example appeared 15 
times, while Apt_10 appeared only 4 times. The majority of the sequences were 
unique sequences, appearing only once. It is possible that the sequences that 
appear more frequently in the aptamer pool is more likely to bind to the protein 
target, TAGLN2.  
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Figure 4. 7: ClustalW alignment of the ten most frequently repeated aptamer sequences. The aptamers were named Apt_1 to Apt_10. The frequency of 
repetition is indicated in brackets. The consensus sequence is indicated on top. The frequency of individual nucleotides in specific positions is also indicated 
and is colour coded. Nucleotides that are highly conserved are not highlighted, while nucleotides that show a degree of variation are highlighted in green. 
Nucleotides with unique nucleotide positions are highlighted in blue. 
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To determine the evolutionary development and diversification of the aptamer 
sequences, phylogenetic analysis of the 10 most frequently repeated aptamer 
sequences was performed (Figure 4.8). For this purpose the 5’ and 3’ primer ends 
were removed to leave a truncated (TR) aptamer sequence, which in essence is 
the variable region of the aptamer library. 
 
 
Figure 4. 8: Phylogenetic trees for the TR aptamers. The name of the aptamer (e.g. Apt_1, 
etc.) and number of repeats (in brackets) for each aptamer are indicated. The boxes indicate Clade 
1 and 2 while 70.0 represent the frequency of evolution of the aptamers in the pool. 
 
TR aptamers showed a distinct evolutionary tree as shown in Figure 4.8. Based 
on the phylogenetic tree, the aptamers appeared to have evolved from Apt_10. 
The evolving aptamers then diverged into two clades; Clade 1 is comprised of the 
Apt_1, Apt_2, Apt_7 and Apt_9, while clade 2 is comprised of Apt_3, Apt_4, 
Apt_5, Apt_6 and Apt_8. Aptamers in clade 1 contained Apt_1 and Apt_2, which 
are also the most recurring (frequent) aptamers with frequencies of 15 and 13. 
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Since the selection pressure during SELEX will strengthen the evolution of 
aptamers with a higher affinity for the target protein, Apt_1 and Apt_2 might 
potentially be more suitable for application in the detection of TAGLN2. Apt_9, 
which was the last aptamer to evolve in clade 1, may also be a possibility. Clade 
2 evolved before clade 1 and eventually produced Apt_4, which may therefore 
also be a possible consideration. The frequency of evolution (70.0) was attributed 
by the rate of mutations during PCR amplifications. 
A pairwise sequence alignment analysis of clade 1 and 2 shows a distinct contrast 
attributed by the conserved regions in clade 1 (Figure 4.9). It is clear that the 
sequence alignment of the clade 1 was more homogenous compared to aptamers 
in clade 2. Therefore, based on this data, aptamer sequences from clade 1 (Apt_1, 
Apt_2, Apt_7 and Apt_9) were selected for further analysis. 
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Figure 4. 9: Pairwise sequence analysis of clade 1 and 2. Clade 1 has conserved regions that start from sequence ~35 to 50. The name of the aptamer (e.g. 
Apt_1, etc.) and number of repeats (in brackets) for each aptamer are indicated.  
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4.2.3.2 Identification of conserved motifs in clade 1. 
The DNA sequence in the variable regions (VRs) of Apt_1, Apt_2, Apt_7 and 
Apt_9 were analysed using Multiple EM for Motif Elicitation (MEME) online 
software (http://meme-suite.org). MEME is an online tool that can be used to 
identify common sequence motifs in a group of related DNA sequences. 
Conserved motifs in DNA aptamers have been shown to be involved in binding 
interactions between the aptamers and the target protein (Groher and Suess, 2016; 
Meng et al., 2014; Murakami et al.,  2017; Percze et al., 2017). Figure 4.10 
shows the results for MEME analysis. Three recurring motifs (5’-GGGGTGG-3’, 
5’-TTTAT-3’ and 5’-TAGTTA-3) were identified in aptamers from clade 1. The 
5’-GGGGTGG-3’ motif appeared more frequently than 5’-TTTAT-3’ or 5’-
TAGTTA-3’. The 5’-GGGGTGG-3’ motif appeared 4 times in Apt_2 and 3 times 
in Apt_1, Apt_7 and Apt_9. It is known that DNA with a high GC content is 
more stable at higher temperatures, which may suggest that the aptamers from 
clade 1 can form high stable structures. The 5’-TTTAT-3’ motif appeared only in 
Apt_2 and Apt_9, while the 5’-TAGTTA-3’ motif only appeared in Apt_2 and 
Apt_7. 
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Figure 4. 10: MEME analysis of aptamer sequences from clade 1. A shows the consensus sequence, B shows the sequence alignment, C shows the 
positioning of the motifs in the VR of the aptamers, while D shows the sequence of the motifs and the variation of nucleotides within the motifs. 
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4.2.3.3 Aptamers secondary structures prediction by M-fold 
M-fold (http://unafold.rna.albany.edu/?q=mfold) is a web-based online software tool 
that can be used to predict the suboptimal secondary structure of DNA by free energy 
minimization. Mfold was also used to confirm the location of conserved motifs within 
the secondary structures. 
The formation of the aptamer secondary structure is dependent on the environmental 
conditions (i.e. pH, ionic strength and temperature) as this drive the formation of the 
helix structures supported by the hydrogen bonds of the stacked sequences (Bozza et 
al., 2006). The conditions for the structure predictions were set according to the 
constituents of the SELEX buffer (PBS) at 25 
0
C in 0.138mM NaCl and 1.5mM ions at 
pH 7.4.  These conditions were selected, as it resembled the conditions used to do the 
aptamer selection in SELEX.  
Since FL aptamer sequences were used during SELEX, structure predictions were done 
on both FL and TR aptamer sequences. The removal of the conserved primer sequences 
can have a significant effect on the folding of the aptamer, consequently affecting the 
binding negatively (Kaur and Yung, 2012). Conversely, the removal of the conserved 
primer sequences can also successfully reduce the length of an aptamer without any 
significant loss of its binding activity to the target (Akitomi et al., 2011). It is therefore 
advisable to perform an in silico prediction of the aptamer secondary structure with 
both FL and TR aptamer sequences. Figure 4.11 shows the in silico predicted structures 
of FL and TR for Apt_1, Apt_2, Apt_7 and Apt_9. 
http://etd.uwc.ac.za/
109 
 
The aptamers were folded into unique structures that included loops and stems as 
shown in Figure 4.11. Structures generated for the FL sequences were more 
complex when compared to the TR sequences. The number of loops and stems in 
the FL sequences were much higher when compared to the TR sequences, which 
mostly consisted of one loop structure. The free energy (dG) predicted for the FL 
sequences was significantly lower (-7.14 to -9.65) when compared to the TR 
sequences (0.18 to -2.10). This suggests that FL structures are more likely to form 
under these environmental conditions. The structure predicted for Apt_2 had the 
lowest free energy (-9.65) suggesting that it will form more readily than the 
others. Amongst the TR sequences, Apt_1 had the lowest free energy (-2.10), 
while the TR sequence for Apt-9 was the only aptamer that produced a positive 
free energy (0.18), suggesting that this aptamer will only form if energy is 
applied in the form of heat. 
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Figure 4. 11: The predicted secondary structures for aptamers from clade 1. FL (A) and TR (B) sequences were analysed using M-fold. The red arrows in 
all the aptamers represent the conserved motifs regions. The free energy (dG) for each structure is also indicated.  
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4.3 Conclusion 
Four DNA aptamers (Apt_1, Apt_2, Apt_7 and Apt_9) that can potentially bind to 
TAGLN2, a potential serum TB biomarker protein were identified through 13 rounds of 
SELEX using a recombinant histidine tagged sample of this protein. The Apt_1 
sequence appeared more frequently in the aptamer pool generated after 13 rounds of 
SELEX. Based on in silico structure prediction, the FL sequences for these aptamers 
are more likely to form using conditions that are comparable to the conditions used 
during SELEX. However, much of this is based on predictions, the actual binding of 
the aptamers to TAGLN2 needed to be verified experimentally using technologies such 
as EMSA, Isothermal Titration Calorimetry (ITC), Bio-Layer Interferometry (BLI) or 
Surface Plasmon Resonance (SPR). 
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CHAPTER 5 
EVALUATING THE BINDING OF APT-1 TO RECOMBINANT 
TAGLN2 PROTEIN 
 
5.1 Introduction 
The Electrophoretic Mobility Shift Assay (EMSA) can be used to evaluate the 
interaction and formation of complexes between nucleic acids and proteins based on 
changes in the electrophoretic mobility of the complex (Hellman and Fried, 2007). The 
electrophoretic mobility of a molecule is determined by its net charge as well as its 
molecular weight. The higher the negative charge on the molecule, the faster the 
movement of the molecule through matrices such as agarose or acrylamide. Therefore, 
when a nucleic acid is bound to a protein the electrophoretic mobility will be reduced 
compared to the unbound nucleic acid, which move faster on the gel (Hellman and 
Fried, 2007). The nucleic acid/protein complex is also larger than either molecule on its 
own or therefore the nucleic acid/protein complex will also migrate slower. 
5.2 In vitro binding evaluation by EMSA 
For logistical reasons not all 4 aptamers from clade 1 (Apt_1, Apt_2, Apt_7 and Apt_9) 
could be analysed by EMSA. Apt_1 was selected from the 4 aptamers to evaluate 
binding to TAGLN2. The selection of Apt_1 over the other 3 aptamers was based on the 
fact that DNA sequence analysis (discussed in Chapter 4) demonstrated that the Apt_1 
aptamer sequence was more frequently amplified from an aptamer pool generated after 
13 rounds of SELEX. 
 
http://etd.uwc.ac.za/
113 
 
The binding of Apt_1 to TAGLN2 was investigated using EMSA (Figure 5.1). Apt_1 (5 
μM) was incubated with increasing concentrations (ranging from 5 to 500 nM) of target 
protein (TAGLN2).  These protein/aptamer mixtures were analysed by polyacrylamide 
gel electrophoresis (PAGE). Figure 5.1 shows that the migration of bands produced for 
samples where the TAGLN2 and Apt_1 was mixed, was much slower than the 
migration of the band produced for free Apt_1 (FA). This suggests that Apt_1 was able 
to bind to TAGLN2. This shift can be observed for all 5 concentrations (5, 50, 15, 250 
and 500nM) of Apt_1.  
Two additional negative controls were performed. In Control 1, an unrelated known 
aptamer (this aptamer targets another cancer biomarker protein, Mucin-1, MUC-1) was 
incubated with TAGLN2. In Control 2, Apt_1 was incubated with HSA (which was 
used as a target in positive SELEX) but was not expected to bind Apt_1. The MUC-1 
protein is known to be overexpressed in malignant cancer cells. The MUC-1 protein is 
coded for by the MUC-1 gene (Yang, et al., 2017). Therefore, MUC-1 aptamer was 
used as a negative control since it has affinity for the MUC-1 protein and was not 
expected to bind to the TAGLN2 protein. 
Figure 5.1 shows that the migration of the band produced for samples from Control 1 
was similar to the band produced for free Apt_1 (FA), suggesting no interaction 
between Mucin-1 aptamer and TAGLN2. However, the band produced for Control 2 
shifted to the same position as was observed for the TAGLN2/Apt_1 mixture. This 
suggests that Apt_1 is able to bind HSA as well as TAGLN2 and is not able to 
discriminate between HSA and TAGLN2. It is therefore possible that not all aptamer 
sequences with an affinity for HSA were removed during positive SELEX.  
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However, EMSA does not provide conclusive evidence of molecular interaction (Xie, et 
al 2016) and must be done in conjunction with other methods such as Isothermal 
Titration Calorimetry (ITC), Bio-Layer Interferometry (BLI) or Surface Plasmon 
Resonance (SPR), which is more definitive.  
 
 
Figure 5. 1: Analysis of Apt_1 binding to TAGLN2 using EMSA. FA: free aptamer; 1: Mucin-1 
aptamer incubated with TAGLN2; 2: Apt-1 incubated with the HSA; 5 nM – 500 nM: increasing 
concentration of the TAGLN2 incubated with the Apt_1. The blue arrow (x) shows the migration of 
free aptamer, while the orange arrow (y) shows the migration of shifted aptamer/protein complex. 
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5.3 Conclusion 
EMSA provided preliminary evidence that Apt_1 binds to TAGLN2. However, 
the control experiment shows that Apt_1 binds also binds to HSA, which was 
used in the positive SELEX rounds.  
EMSA does not provide information on the affinity or the rate of 
molecule/molecule interactions. It is also a very crude method to show that two 
molecules interact. Additional experimental work using technologies such as BLI 
and SPR is required to verify the interactions between Apt_1 and TAGLN2, and 
Apt_1 and HSA.  
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CHAPTER 6 
CONCLUSIONS AND FUTURE WORK 
 
The TAGLN2 recombinant protein was successfully expressed by recombinant 
DNA technology. The recombinant protein was successfully purified and 
lyophilized for further application in protein-aptamer interaction studies. The 
recombinant protein was used as a target for aptamers synthesis. Potential TB 
aptamers (Apt 1, 2, 7 and 9) were successfully synthesized by SELEX. The 
binding of these aptamers to TAGLN2 was further validated by Bioinformatics 
tools. Although EMSA showed potential binding of the aptamers to the target 
protein, the SPR ProteOn XPR36 analysis was inconclusive. 
Binding of the aptamers to the TAGLN2 protein will be further characterized by 
other technologies such as the Biacore SPR or Isothermal Titration Colorimetry 
(ITC), UV-Vis absorption, BioLayer Interferometry (BLI), Quartz Micro Crystal 
Balance (QMCB) and the Nuclear Magnetic Resonance (NMR). These studies 
will facilitate the interaction mechanisms as well as demonstrate the potential 
selectivity, specificity and sensitivity of the aptamer to its target molecule. These 
techniques will also be used to determine the binding stoichiometry and kds 
between the aptamers (FL and VR) and TAGLN2 protein as well as the protein-
aptamer complex. Most importantly, the aptamers will be used in the 
development of a rapid and cost-effective nanotech-based detection system for 
diagnosis of TB positive patients at the POC. 
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